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Abstract 
 
Timely coronary artery reperfusion is essential to prevent myocyte  death 
following myocardial infarction. The act of restoring blood flow however, 
paradoxically reduces the beneficial effects of reperfusion. This phenomenon, termed 
myocardial reperfusion injury, refers to the injury of cardiac myocytes that were 
viable immediately before reperfusion.  
Recent studies have shown that the timing and hemodynamic sequence of 
events which govern reperfusion can help to minimize the severity of reperfusion 
injury.  The term postconditioning describes a modified form of reperfusion that 
involves a series of flow interruptions which confer significant cardioprotection to the 
heart. This thesis investigates ischemic postconditioning and endothelial nitric oxide 
synthase (eNOS) phosphorylation as cardioprotective therapies against reperfusion 
injury. Page | iv 
 
 
 
In the first half of this thesis, we test the hypothesis that phosphorylation of 
eNOS  serves as a cardioprotection nodal point for ischemic postconditioning. We 
show that phosphorylation of eNOS increases enzyme activity and that its product, 
nitric oxide, plays a critical role in cardioprotection. A number of cardiac 
dysfunctions arise after reperfusion and we address the effects of postconditioning 
on infarct size and myocardial blood flow.  
The second half of this thesis introduces the use of magnetic relaxometry 
sensors to detect cardiac biomarkers. The ability to non-invasively measure infarct 
size in small animals would be helpful in studying models of myocardial ischemia-
reperfusion injury. We investigate the use of implantable biosensors in vivo and 
show that the cumulative detection of cardiac biomarkers correlates with infarct 
severity. 
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Chapter 1 
  Introduction 
Coronary artery disease is the leading cause of death in the world and is 
responsible for the death of 3.8 million men and 3.4 million woman each year [1].  
Ischemic heart diseases are the most common cause of heart failure accounting for 
over 50% of heart failure cases alone [2]. Reperfusion is essential in order to prevent 
tissue necrosis following myocardial infarction (MI) and coronary artery reperfusion 
following MI has been widely used to restore blood flow and limit infarct progression. 
The timing and effectiveness of myocardial reperfusion are major requirements for 
functional recovery and great efforts are made to achieve reperfusion in a timely 
fashion [3]. The most successful strategies for treating patients following acute MI 
involve early restoration of myocardial reperfusion with the use of thrombolytic Page | 2 
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therapy or percutaneous coronary intervention. However, the act of restoring blood 
flow paradoxically induces further injury, indicating that tissues and cells tolerate 
some levels of ischemia only to lose viability after reperfusion [4]. This phenomenon, 
termed myocardial ischemia-reperfusion injury, can counteract the beneficial effects 
of myocardial reperfusion (Figure 1.1). 
Ischemia-reperfusion  (IR) injury is a multifaceted process which involves 
multiple cell types, for which damage can be transient or lethal in nature [5]. Recent 
studies have demonstrated that the timing and hemodynamic sequence of events 
which govern reperfusion can help to minimize the severity of reperfusion injury. The 
term postconditioning describes a modified form of reperfusion that involves a series 
of flow interruptions during the first few minutes of reperfusion. Postconditioning has 
been shown to confer significant cardioprotection by reducing infarct size and cellular 
apoptosis  [6]. However, given the short time since the discovery of ischemic 
postconditioning, the precise molecular mechanisms responsible for providing 
cardioprotection are not yet known.  
 
1.1.  Problem Statement and Hypothesis 
Recent studies have implicated endothelial nitric oxide synthase (eNOS), a 
nitric oxide synthesizing enzyme, as a potential mediator of ischemic 
cardioprotection. Nitric oxide plays an important role in normal cardiovascular 
function and during myocardial ischemia. In this thesis, we test the hypothesis Page | 3 
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that  eNOS  phosphorylation  plays an integral role in conferring cardioprotection 
during postconditioned reperfusion.
 
  We  investigate whether modulation of eNOS 
phosphorylation, a physiologic mechanism for regulation of in vivo eNOS catalytic 
activity, can serve as an effective treatment for preventing IR injury. Our overall goal 
is to utilize novel contrast-enhanced ultrasound imaging tools to investigate to role of 
eNOS and its involvement in the cardioprotection of IR injury and postconditioning. 
Our proposed approach makes use of eNOS knockout and knock-in mice models to 
investigate the physiological events that occur during IR injury in vivo. Therefore, in 
this thesis, we aim to serially investigate the pathogenesis of IR injury and define the 
relationship between eNOS, eNOS phosphorylation and the early events that occur at 
the onset of reperfusion.  
   Page | 4 
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1.1  Potential contribution of ischemia-reperfusion injury to infarct size. 
Theoretical schematic showing the potential reductions in final infarct size realized 
through early and successful reperfusion of an ischemic myocardium. Despite 
reperfusion, the full benefits are not achieved without cardioprotective intervention 
due to the presence of ischemia-reperfusion  injury. Cardioprotective measures 
performed at the onset of reperfusion can prevent reperfusion injury further 
reducing infarct size. Infarcted myocardial tissue is represented in white, while the 
viable, at risk myocardium is stained red, and the healthy myocardium blue. 
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1.2.  Specific Aims 
 
1.  To investigate the pathogenesis of lethal reperfusion-injury and the role of eNOS 
phosphorylation in ischemic postconditioning after myocardial infarction in vivo. 
 
 
2.  To investigate the role of eNOS phosphorylation and postconditioning on 
myocardial blood flow and the no reflow phenomenon in myocardial ischemia-
reperfusion injury. 
 
 
3.  To develop an implantable biosensor capable of measuring cardiac biomarkers in 
vivo and correlate biomarkers with infarct size severity. 
   Page | 6 
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1.3.  Myocardial Ischemia-Reperfusion Injury: Past 
to Present 
 
 
 
1.2 Classic presentation of myocardial ischemia. Excerpt from James B. Herrick’s 
landmark 1912 description of the “Clinical Features of Sudden Obstruction of the 
Coronary Arteries.” Myocardial ischemia is caused by blockage of a coronary artery 
or of any of its large branches. Blockage of these vessels prevents blood flow to the 
myocardium causing tissue ischemia and cell death if not treated promptly, 
reproduced from Herrick [7].  
 
The classic description of patients presenting with acute myocardial 
infarction and its cause was described by James Herrick in his landmark JAMA 
article in 1912 [7].  Herrick attributed the cause of myocardial infarction to a 
coronary thrombotic event (Figure 1.2). Since then, it has been established that the 
severity and duration of myocardial ischemia are important determinants of final 
infarct size [8]. Reimer et al documented the wave-front phenomena of ischemic cell Page | 7 
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death whereby myocyte necrosis progresses from the endocardium towards the 
epicardium as the duration of coronary occlusion increases [9].  
The diagnosis and treatment of acute MI has evolved to employ the use of 
methods to either dissolve, compress, remove or bypass the occluding thrombi to 
achieve early myocardial reperfusion, reduce the size of the infarction and improve 
clinical outcome [10]. However, the process of reperfusion itself can induce further 
injury to the ischemic myocardium. This phenomenon, referred to as myocardial 
reperfusion injury, can reduce the beneficial effect of myocardial reperfusion. 
The concept of myocardial ischemia-reperfusion injury was proposed in 
1960 by Jennings who reported structural and electrophysiological changes to the 
heart after coronary reperfusion [11]. In their histological findings Jennings et al 
reported that reperfusion caused irreversible damage to myocytes, which displayed 
explosive swelling, contraction bands of the myofibrils and architectural disruption 
to the sarcolemma suggesting that the act of reperfusion itself may contribute to 
myocardial apoptosis and necrosis. 
Reperfusion of the heart primarily causes four types of cardiac dysfunction, 
these consist of: 1) myocardial stunning, 2) reperfusion arrhythmias, 3) no-reflow 
phenomena  and 4) lethal reperfusion injury [12]. The first, myocardial stunning 
refers to relatively mild, sub-lethal injury to myocytes in the presence of near-
normal blood flow where contractile abnormality is reversible. The dysfunction is 
not caused by a primary deficit in myocardial blood flow and the myocardium Page | 8 
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usually recovers from this form of injury in days to weeks [13]. The second type of 
cardiac dysfunction describes arrhythmias that can arise as a consequence of 
myocardial reperfusion and the resulting electrophysiological imbalance. The cause 
and treatment of reperfusion-induced arrhythmias has been reviewed in depth by 
Manning et al [14]. The third type, no-reflow phenomenon, refers to the breakdown 
or obstruction of the coronary microvasculature in the infarct zone despite an open 
infarct related artery. Successful restoration of coronary artery patency does not 
necessarily translate into improved tissue perfusion with no-reflow phenomenon 
[15]. The last type of cardiac dysfunction, lethal reperfusion injury, relates to the 
paradoxical reduction in the beneficial effects of myocardial reperfusion following 
MI. Lethal reperfusion injury results from factors initiated  at the onset of 
reperfusion that lead to the death of cardiac myocytes that were viable immediately 
before reperfusion [16].  
In this thesis, we focus on the effects of postconditioning and eNOS activity 
on no-reflow phenomenon and lethal reperfusion injury. We  address  lethal 
reperfusion injury in Chapter 2 while Chapter 3 focuses on myocardial blood flow 
and the no-reflow phenomenon. 
   Page | 9 
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1.4.  Thesis Outline 
This thesis focuses on cardioprotective strategies for the treatment and 
monitoring of acute myocardial infarction and can be divided into two sections. The 
thesis roadmap is summarized in Figure 1.3.    
The first half of this thesis focuses on methods of ischemic cardioprotection. 
We investigate the cardioprotective role of postconditioning and eNOS 
phosphorylation in reperfusion injury. In chapter 2 we address lethal reperfusion 
injury and the ability of postconditioning to reduce infarct size. We also investigate 
eNOS phosphorylation as a central integrating nexus that influences infarct size and 
ischemic cardioprotection.  
 
1.3 Thesis roadmap. 
   Page | 10 
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Chapter 3 addresses the effects of postconditioning on myocardial blood 
flow. In this chapter we utilize myocardial contrast echocardiography to obtain a 
temporal understanding of the myocardial blood flow dynamics that occur after 
reperfusion. We address the challenge of accurately estimating blood flow when 
provided with non-EKG gated ultrasound videos and propose the use of an 
automated active contours image segmentation algorithm to identify and track the 
myocardium. 
The second half of this thesis describes the development and 
characterization of implantable biosensors for the detection of cardiac biomarkers. 
Chapter 4 presents a proof-of-concept biosensor based on magnetic relaxation 
switch technology that allows for estimation of infarct size in vivo.  
    
 
 
 
 
 
 
 
Chapter 2 
  Ischemic Postconditioning: Protection Against 
Myocardial Ischemia-Reperfusion Injury 
 
This chapter describes the use of genetic mouse models to study the role of 
eNOS activity and nitric oxide production in ischemic postconditioning. We develop 
a murine model of myocardial ischemia-reperfusion injury and study the effects of 
ischemic postconditioning on lethal reperfusion injury. Our study employs the use of 
S1176D  phosphomimetic eNOS knock-in mice which simulate the effects of 
constitutively phosphorylated eNOS to generate increased levels of nitric oxide in 
myocardial tissue. We determine the effects of phosphomimetic eNOS modulation 
on known cardioprotective molecular pathways as well as its effect on infarct size 
following IR injury. 
 Page | 12 
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2.1.  Motivation 
eNOS and its product, nitric oxide, play an important role in cardioprotective 
signaling, platelet aggregation  and leukocyte-endothelial interaction  [17,  18]. 
Among the regulators of NO, phosphorylation of eNOS appears to be an important 
means of regulating enzyme activity [19, 20]. In this chapter we test the hypothesis 
that increased eNOS phosphorylation provides a protective benefit against lethal 
ischemia-reperfusion injury. In particular, the importance of eNOS phosphorylation 
at the Serine1176 residue has been studied in vitro using a mutant form of eNOS.  
S1176D eNOS contains a single aspartate for serine amino acid substitution 
that mimics the negatively charged phosphate group of phosphorylated eNOS. The 
resultant eNOS enzyme has higher catalytic activity and increased production of NO 
at basal levels.  We have generated S1176D mice which express this mutant form of 
eNOS and use these mice to develop an understanding of the molecular mechanisms 
that influence infarct size following myocardial IR injury. The combined use of eNOS 
knock-out and S1176D knock-in mice models help provide an in vivo understanding 
of how eNOS phosphorylation is  centrally integrated into the  cardioprotective 
survival pathway. 
 
   Page | 13 
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2.2.  Targeting Reperfusion Injury with Ischemic 
Postconditioning 
 
Postconditioning describes a series of brief mechanical interruptions to blood 
flow performed at the onset of reperfusion. Postconditioning initiates a cascade of 
cardioprotective signals that ultimately lead to a reduction in infarct size and myocyte 
apoptosis. The concept of postconditioning was first reported in 2003 by Zhao et al. 
who demonstrated in canines that postconditioning conferred similar 
cardioprotection against MI injury when compared to preconditioned hearts [21]. 
Since then, these occlusion-reocclusion algorithms have been shown to attenuate 
damage successfully in rabbits, mice and humans [22, 23]. The algorithms employed 
in these studies typically last for a few minutes with the optimal duration of occlusion 
varying between species. Postconditioning algorithms differ  from those of 
preconditioning because they can be applied at the onset of reperfusion in 
conjunction with other clinical services such as angioplasty. Importantly, they do not 
require foreknowledge of the ischemic event. A typical flow profile comparing 
traditional vs. postconditioned reperfusion as applied to mice is shown in (Figure 
2.1), 10 second intervals are used between reperfusion cycles for postconditioning in 
mice. 
IR injury is a complex process and the means by which postconditioning exerts 
its protective effects remain  unclear. Multiple physiological pathways have been 
suggested to be involved, including reduction in the degree of: endothelial cell  Page | 14 
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2.1  Traditional and postconditioning reperfusion algorithms. Following 45 
minutes  of  ischemia, mice are subjected to either traditional reperfusion or 
cardioprotective postconditioning.  A) Traditional reperfusion is achieved by 
immediate reperfusion of the myocardium. B) Postconditioning is accomplished by 
implementing 6 cycles of 10 sec  reperfusion followed by 10 sec occlusion. The 
extent of reperfusion injury is evaluated 24 hours after reperfusion.  
 
dysfunction,  reactive oxygen species generation, leukocyte activation and 
mitochondrial damage [24-26]. While the net effectiveness of postconditioning has 
been reported by multiple independent laboratories, the importance and role of 
myocardial blood flow as well as nitric oxide availability remain unknown. A temporal 
understanding of  the effects of postconditioning on  IR injury will help us better 
understand the chronology of events that are required to protect the heart after MI. In 
addition, the protective role of eNOS phosphorylation and its central role in 
postconditioning have yet to be investigated. The purpose of this chapter is to define 
the role of eNOS phosphorylation at Serine1176  in postconditioning and against 
myocardial IR in vivo.  Page | 15 
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2.3.  eNOS: Structure to Function with one Aspartic 
Substitution 
 
eNOS  catalyzes the reaction of oxygen with L-arginine to generate nitric 
oxide and L-citrulline  [27]. It is part of the first mammalian pathway known to 
synthesize a gas as a signaling molecule. Structural studies have suggested that 
active eNOS is associated with dimerization that facilitates electron flow through the 
active site pocket. This interface includes the binding site for BH4, heme and L-
arginine (Figure 2.2). The presence of BH4, heme and L-arginine stabilize the active 
dimeric form of eNOS. eNOS activity can be regulated by Ca2+ dependent interaction 
at the calmodulin (CM) binding domain as well as by phosphorylation. Studies have 
shown that Serine1176  is phosphorylated by protein kinase AKT [19,  20], which 
results in increased electron flux through the reductase domain and an increase in 
NO production [28]. 
In order to mimic the gain of function achieved through phosphorylation of 
Serine1176, we have implemented a single aspartic acid for serine substitution 
(Figure 2.2). The negative charge associated with the carboxyl group on aspartic 
acid mimics the charged  phosphate group of activated Serine1176  (serine 
phosphorylation occurs at eNOS S1176 in mice, S1177 in humans and S1179 in cow) [28, 
29]. This mutation removes  the steric hindrance imparted by the non-catalytic 
insert and permits better electron flux through the reductase domain to facilitate NO 
generation in the oxygenase domain [30]. Page | 16 
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2.2  Schematic Representation of eNOS homodimer and Aspartic S1176D 
substitution.  We have engineered genetic S1176D knock-in mice with a single 
aspartic acid substitution to mimic phosphorylation of eNOS at S1176, eNOS 
homodimer image adapted from Goligorsky [31]. 
 
 
2.4.  Mediators of Lethal Reperfusion Injury 
 
The lethal aspect of reperfusion-injury refers specifically to the injury caused 
by the act of reperfusion after an ischemic episode. Studies in MI animal models 
suggest that reperfusion injury can account for up to 50% of the size of the final 
infarct  [1]. The development of therapeutic treatments for ischemia-reperfusion 
injury have been targeted at a multitude of biological pathways; these range from 
minimizing the oxidative stress generated during reperfusion to attenuating a myriad 
of factors that result from the innate inflammatory response [32].  
Experimental models have demonstrated that modified forms of reperfusion, 
such as postconditioning, can reduce reperfusion injury and confer cardioprotective 
effects, raising hopes for clinical therapy. Recent demonstrations of the beneficial Page | 17 
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effects of ischemic postconditioning during reperfusion have generated immense 
interest in the reperfusion phase as an opportune window for establishing 
cardioprotection. However, a more concrete understanding of the factors responsible 
for regulating lethal reperfusion injury is necessary before we can design successful 
therapies  to attenuate the damage caused by reperfusion.  Here we provide an 
overview of the mediators of lethal reperfusion injury  and the potential role of 
postconditioning in limiting these factors.  
 
2.4.1.  Inflammation 
The innate inflammatory response following an acute MI is characterized by 
the release of chemo attractants and the recruitment of neutrophils and macrophages 
to the injured myocardium. The degree of leukocyte activity is likely affected by the 
choice of reperfusion (traditional or postconditioned). The inflammatory response 
rapidly recruits neutrophils to the site of damage within the first 6 hours where they 
begin to remodel the local microenvironment and facilitate healing over the next 24 
hours. Efficient cardiac repair involves the generation of oxygen free radicals, the 
release of proteases and the additional recruitment of inflammatory cells [33]. In the 
process  however,  the release of degradative enzymes and generation of reactive 
oxygen species can cause vascular plugging and other detrimental effects.  
An understanding of how reperfusion affects  leukocyte recruitment will 
provide valuable information for future MI treatment. Studying postconditioning and Page | 18 
 
 
 
Chapter 2: Ischemic Postconditioning  
its effect on vascular function will enable us to augment this repair process in the 
future.  
 
2.4.2.  Mitochondrial Permeability Transition 
The mitochondrial permeability transition pore (mPTP) is  a  non-specific, 
high conductance protein channel of the inner mitochondrial membrane that is 
normally closed under physiologic conditions but opens under cellular stress [34]. 
During ischemia, the mPTP remains closed, but opens shortly after reperfusion as a 
result of mitochondrial Ca2+ overload, stress from reactive oxygen species, and the 
rapid restoration of tissue pH. Opening of the mPTP  allows  for  free passage of 
molecules across the inner mitochondrial membrane which initiates a variety of 
adverse effects such as osmotic pressure changes, mitochondrial swelling and 
ultimately cell death. The mitochondrial permeability transition causes the collapse 
of the mitochondrial membrane potential, uncouples oxidative phosphorylation and 
accelerates the hydrolysis of ATP [35]. It leads to the release of inner mitochondrial 
proteins and the irreversible activation of pro-apoptosis pathways. Pharmacological 
intervention of the mPTP with cyclosporine A or specific inhibitors of the mPTP 
have been shown to protect against the onset of lethal reperfusion injury [36]. 
Postconditioning has been shown to inhibit the mPTP in rabbits [37]. 
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2.4.3.  Generation of Reactive Oxygen Species 
Oxygen free radicals have been studied extensively as mediators of lethal 
reperfusion injury.  There is an increase in the generation of free radicals once 
oxygen is reintroduced to ischemic myocardium [38,  39].  Most reactive oxygen 
species (ROS) are generated by neutrophils and the mitochondria and the burst of 
ROS within the first moments of reperfusion is associated with cardiac dysfunction. 
In addition, the propagation of ROS induced ROS release may amplify its harmful 
effects  [40]. This has led to the suggestion  of  the  oxygen paradox,  where re-
oxygenation of the myocardium is necessary but its action  generates  additional 
oxidative stress that contributes to myocardial injury exceeding the injury induced 
by ischemia alone [12]. Furthermore, oxidative stress has been shown to reduce the 
bioavailability of nitric oxide, reducing the cardioprotective effects of NO [41]. The 
protective effects of NO include the inactivation of superoxide radicals, inhibition of 
neutrophil accumulation and improved tissue blood flow. 
 
2.4.4.  pH restoration 
During myocardial ischemia, the ischemic tissue  becomes acidotic and 
develops a large reduction in pH [42]. Ischemia causes anoxia and the generation of 
lactic acid through anaerobic glycolysis and ATP depletion. Reperfusion washes out 
any lactic acid that has built up in the ischemic myocardium causing a rapid return 
to physiologic pH. The recovery of pH to normal levels is a stress that can precipitate Page | 20 
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myocyte death. Although tissue acidosis may seem detrimental in ischemia, 
numerous studies have highlighted a “pH paradox” where acidosis strongly protects 
against lethal reperfusion injury. Bond et al showed protection with acidotic pH 
perfusate  when neonatal rat cardiac myocytes were reoxygenated in a pH 6.2 
environment versus a pH of 7.4 [43].  The mechanisms responsible for this pH 
paradox remain poorly understood but acidosis may inhibit harmful proteases and 
other destructive enzymes that require a neutral or alkaline pH [44,  45]. pH-
dependent reperfusion injury may involve the reactivation of pH dependent 
enzymes that accelerate intracellular damage. In addition, the rapid restoration of 
physiologic pH may be responsible for the opening of mitochondrial permeability 
transition pore [35]. 
 
2.4.5.  Intracellular Ca2+ Overload 
Reperfusion also causes intracellular and mitochondrial Ca2+ overload. The 
increase of intracellular Ca2+ is caused by sarcolemmal-membrane damage and ROS 
related dysfunction of the sarcoplasmic recticulum. Excess myocardial Ca2+ 
precipitates myocyte death by causing sarcolemmal contraction and opening of the 
mitochondrial permeability transition pore [12]. Treatment of reperfusion injury 
with intracoronary calcium channel agonists can decrease infarct size in 
experimental models [46] but the results of clinical trials have been unsuccessful 
[47].  Page | 21 
 
 
 
Chapter 2: Ischemic Postconditioning  
2.5. The Role of Nitric Oxide Response in 
Reperfusion Injury  
 
Although reperfusion is essential in preventing tissue death, the restoration of 
blood flow to the ischemic myocardium results in further injury to the surrounding 
area [3]. Following reperfusion, the time course of vascular dysfunction begins early 
after  the onset of reperfusion. The endothelium becomes dysfunctional within 
minutes, resulting in a marked decrease in NO bioavailability; this is supported by 
experimental evidence demonstrating impaired endothelium dependent vasodilatory 
relaxation after ischemia-reperfusion  [48].  This represents a pressing concern 
because post-MI survivors with persistent vascular dysfunction are more likely to 
develop heart failure. 
NO plays numerous roles in the heart and low levels of NO are required to 
regulate vascular tone, inhibit leukocyte-endothelial adhesiveness and prevent 
mitochondrial mediated apoptosis [3].  NO bioavailability is necessary for 
cardioprotection and experimental treatments have identified eNOS activation as an 
integral component of pro-survival pathways against lethal reperfusion injury. For 
example, the pharmacological use of HMG-CoA reductase inhibitors has been shown 
to regulate eNOS mRNA levels [49]  and attenuate the severity of myocardial IR 
injury  [50,  51]. Other pharmacological studies have documented the powerful 
cardioprotective effects of gaseous hydrogen sulfide [52] and volatile anesthetics 
such as isoflurane at the onset of reperfusion. [53, 54] while the use of insulin  Page | 22 
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2.3  Overview of survival kinases pathway in ischemic postconditioning.  A 
simplified scheme of important transduction pathways recruited in the setting of 
cardioprotective ischemic postconditioning. Generation of nitric oxide (NO) through 
eNOS contributes to the protection of the ischemic heart, adapted from [55]. 
 
 
therapy has been shown to inhibit leukocyte-endothelial adherence via an NO-
dependent mechanism [56-58].    
 The interactions of NO  with various pathways are an important defense 
against IR injury and serve as endogenous protectants for the heart. In the 
myocardium, the protective effect of NO is supported by the fact that knock-out mice 
deficient in eNOS develop infarct sizes significantly larger than wild-type mice 
following reperfusion injury [59]. NO protection is also important in the inhibition of 
the mitochondrial permeability transition through the reperfusion injury salvage Page | 23 
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kinase (RISK) signaling pathway (Figure 2.3). NO interacts with soluble guanylate 
cyclase and its downstream effectors to inhibit the opening of the mPTP [55]. 
Since postconditioning reduces infarct size caused by lethal reperfusion injury, 
we assess the role of postconditioning and its ability to regulate NO bioavailability. 
This chapter focuses on the importance of eNOS S1176 phosphorylation as a critical 
step in the regulation of eNOS activity and treatment of IR injury.  
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2.6.  Genetic Mouse Models of Endothelial Nitric 
Oxide Synthase 
 
In order to study the importance of eNOS phosphorylation on the in vivo 
disease pathogenesis of ischemia reperfusion injury we utilize two murine models 
of mutant eNOS: an eNOS knock-out model and S1176D phosphomimetic knock-in 
model of eNOS. The knock out model of eNOS mice was previously generated in our 
lab by Huang et al [60]. eNOS mediates basal vasodilation and the blood pressure in 
eNOS knock-out mice is significantly higher that wild-type mice. Studies of cardiac 
function  in  eNOS knock-out mice demonstrate that baseline cardiac contractility 
measures are similar between knock out and wild-type mice [61].  
We used the S1176D knock-in model to study the specific effects of eNOS 
phosphorylation on reperfusion injury. Figure 2.4 depicts the construct used by our 
lab to generate this phosphomimetic form of eNOS. The eNOS gene of S1176D ki 
mice contains a single amino acid mutation, where serine1176  is replaced by 
aspartate (S1176D) to achieve a phosphomimetic gain-of-function mutation [19, 
20]. Aspartate contains a carboxyl moiety that mimics the negatively charged group 
when eNOS is normally phosphorylated at serine1176. Previous in vitro studies in 
endothelial cells expressing the S1176D form of eNOS are characterized by 
increased basal enzyme activity and augmented NO production at resting levels of 
intracellular calcium [62]. In addition, we have previously shown in vivo that this 
phosphomimetic S1176D form rescues impaired blood flow in Akt1 deficient mice Page | 25 
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subjected to wound healing assays [63], and improves vessel reactivity and 
decreases stroke size when challenged with cerebral ischemia [64]. Both the eNOS 
knock-out and S1176D knock-in mice were backcrossed to C57BL/6J background to 
eliminate the confounding variability of genetic background. 
 
2.4  Generation of 
phosphomimetic eNOS 
mice.    Schematic of the 
transgenic construct used 
to generate eNOS knock-
in mice. A 1.6-kb fragment 
from the eNOS promoter 
drives the eNOS cDNA 
carrying a 
phosphomimetic eNOS 
mutation, an HA tag and 
SV40 polyadenylation site, 
adapted  from Atochin et 
al. [64]. 
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2.7.  Mouse Model of Myocardial Ischemia-
Reperfusion Injury and Postconditioning 
 
Mouse models of IR injury are advantageous compared to other animal 
models (such as rat, rabbit and larger animal models) because of their small size, 
rapid gestation period (21 days) and large litter numbers. Advancements in gene-
targeted knock-out and knock-in  techniques to modify the  mouse genome have 
made it possible to study the role of eNOS phosphorylation in cardiovascular 
disease. With our arsenal of genetically altered eNOS mice, we were interested in 
developing a murine model of ischemic postconditioning to study the mechanisms 
responsible for myocardial IR injury. A murine model of postconditioning enables us 
to model myocardial IR injury and study the importance of phosphomimetic eNOS 
modulation in vivo.  
We developed a mouse model based off of the techniques pioneered by Lloyd 
et al adopting a model of left anterior descending  (LAD)  artery occlusion and 
reperfusion [65]. We applied a LAD artery occlusion for 45 minutes followed by 
reperfusion allowing flow through the previously ischemic myocardium. 
Postconditioning was achieved by integration of a snare onto the silk ligature 
around the LAD (Figure 2.5). Myocardial ischemia was documented visually as well 
as by laser Doppler and contrast ultrasound in specific cases. Figure 2.6A shows the 
position of the suture and snare on the LAD coronary artery and the subsequent 
change in color of the anterior wall achieved by tightening of the ligature (Figure  Page | 27 
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2.5 Location of Surgical Incision and Ligation.  A) The mouse is intubated and a 
surgical thoracotomy is performed left of the sternum.  The pericardium is then 
separated to allow access to the myocardium, image adapted from Tarnavski et al. 
[66] B) 7-0 silk suture is passed under the left anterior descending (LAD) coronary 
artery at the level below the left auricle. C) A snare using PE10 tubing is then formed 
around the suture, application of tension on suture forces the snare onto the LAD 
creating temporary occlusion of the LAD. Reperfusion of the myocardium is 
achieved on relaxation of the snare. 
 
 
2.6B). In our model of IR injury, mice are sacrificed 24 hours after reperfusion to 
evaluate infarct size. 
When performing IR injury studies and comparing infarct size, consistency of 
the area at risk between groups is important [66]. The gold standard technique for 
evaluating area at risk and infarct size is accessed via perfusion of Evans blue dye 
into the carotid artery while the myocardium is re-ligated. Areas of the myocardium Page | 28 
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not stained blue are then classified as the ‘area-at-risk’ (figure 2.7B). The heart is 
then excised and sectioned transversely into 1mm sections, weighed and stained 
with triphenyltetrazolium chloride (TTC). After TTC staining, viable myocardium 
stains red (figure 2.7C) while infarcted myocardium appears white (figure 2.7D). 
The final size of infarction was determined by a weighted average of the myocardial 
slices (see methods for detailed description). 
 
 
  
2.6  Ligation of the Left Anterior Descending Coronary Artery. The arrow 
identifies the LAD coronary artery. A) Normal perfused myocardium, on visual 
inspection the myocardium appears a robust pink color from a perfused vascular 
bed. B) Ischemic myocardium achieved by application of snare around LAD 
coronary artery. An empty  coronary artery is identified by the arrow and a 
significant pallor of the myocardium can be confirmed visually. 
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2.7 Ex vivo evaluation of infarct size. 1mm slice of excised myocardium from the 
level of the dotted line. B) Separation of the left ventricle. C) Area at risk (stained 
red) D) Infarct Size (stained white). 
 
 
 
2.8.  Results 
2.8.1. Modulation of Nitric Oxide Levels 
 
eNOS phosphorylation modulates myocardial nitric oxide levels.  
To investigate the relevance of eNOS phosphorylation as a specific target for 
protection against myocardial IR  injury, we generated genetic knock-in mice 
expressing a S1176D phosphomimetic mutant form of eNOS. The serine at 1176 of 
the endogenous eNOS gene was replaced by a single amino acid mutation (S1176 for 
aspartate replacement, S1176D knock-in) that simulated phosphorylation (Figure 
2.8A) [62].  
To assess whether S1176D knock-in mice can be used as a suitable model for 
examining eNOS function in the heart, we evaluated the basal level of myocardial NO Page | 30 
 
 
 
Chapter 2: Ischemic Postconditioning  
production in S1176D knock-in mice versus WT and eNOS ko mice. We used NO 
specific fluorometry to detect levels of nitrate/nitrite (NOx), the stable breakdown 
products of NO metabolism [67]. Myocardial tissue isolated from S1176D ki mice  
 
 
2.8 Phosphomimetic modulation of eNOS increases available nitric oxide in 
the myocardium. (A) We generated eNOS knock-in mice with a single amino acid 
mutation replacing Serine1176 with a phosphomimetic aspartate mutation. The 
aspartate contains a negatively charged carboxyl group that mimics the 
phosphorylated form of eNOS, increasing electron transfer through the calmodulin 
(CaM) domain and nitric oxide production. (B) Constitutively active S1176D ki eNOS 
mice were compared against WT and eNOS ko mice. Myocardial nitrite/nitrate 
levels were measured via fluorometric assay and normalized by tissue wet weight. n 
= 7 - 11 mice per group. Data are expressed as the mean ± SD. * P < 0.05 compared 
to WT. Page | 31 
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showed greater basal levels of NO when compared to eNOS ko mice and expressed 
higher levels of NO when compared to WT mice (Figure 2.8B). These results are 
consistent with previously reported findings from isolated S1176D ki mouse lung 
endothelial cells, which showed greater basal production of NO compared to wild-
type mice.  Additionally, earlier vascular reactivity studies in S1176D transgenic 
mice showed increased relaxation in response to stimulation with Acetylcholine 
compared to WT mice [64]. Here, these data extend our findings by demonstrating 
that baseline levels of NO in the myocardium can be regulated by constitutive 
activation of eNOS activity.  
 
2.8.2. In Vivo Tolerance to Reperfusion Injury 
Postconditioning and S1176D mice show increased tolerance against IR injury in vivo. 
To determine whether myocardial postconditioning is conserved with 
increased constitutive eNOS phosphorylation, we examined the response to 
myocardial IR injury in S1176D ki mice. Previous studies in eNOS ko mice have 
shown that the absence of eNOS exacerbates murine IR  infarct size [68]  while 
increased expression of eNOS in transgenic eNOS mice improves tolerance against 
IR injury [69]. WT, S1176D ki and eNOS ko mice were subjected to ligation of the left 
anterior descending (LAD) artery for 45 minutes, followed by traditional 
reperfusion by reopening of the ligation (MIR) or postconditioning (MIPc, 6 cycles of  Page | 32 
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2.9 eNOS S1176 phosphorylation protects against IR injury in vivo. WT, S1176D 
and eNOS ko mice were subjected to myocardial IR injury (45 minutes ischemia) 
using a left anterior descending artery ligation model followed by (24 hours) 
traditional reperfusion (MIR) or postconditioned reperfusion (MIPc: 6 cycles of 
10sec reperfusion, 10 sec ischemia). (A) Percentage of left ventricle area at risk, (P = 
NS). (B) Quantitative analysis of infarct size over area at risk, * P < 0.05 compared to 
WT control. Cardioprotection was activated in S1176D hearts and lost in eNOS ko 
mice. (C) Representative heart sections perfused with 1% Evans blue and stained 
with 2% TTC, infarct areas are outlined in black. MIR: Myocardial ischemia with 
reperfusion, MIPc: Myocardial ischemia with postconditioning, AAR: Area at Risk, 
LV: Left Ventricle. n = 6 - 9 mice per group. Data are expressed as the mean ± SD. 
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10 sec reperfusion followed by 10 sec ischemia). The area at risk determined 24 
hours after IR was not significantly different across groups (Figure 2.9A). WT mice 
subjected to postconditioning developed smaller infarct sizes (ratio of infarct 
size/area at risk) compared to mice subjected to IR. However, when eNOS ko and 
S1176D ki mice were subjected to myocardial IR  injury the effects of 
postconditioning on infarct size displayed marked differences. Postconditioning was 
effectively abolished in eNOS ko mice with no reduction in infarct size (Figure 2.9B). 
In contrast, S1176D ki mice displayed cardioprotective infarct sparing effects 
in both the traditional and postconditioned groups with reductions in infarct size 
comparable to those in postconditioned WT mice. The IR data from S1176D ki mice 
show that eNOS activity significantly reduces infarct size, regardless of reperfusion 
technique. These results suggest that S1176D mice subjected to myocardial IR injury 
are conferred protection against IR  injury, even in the absence of protective 
postconditioning (MIPc) therapy. Representative infarct slices with the infarct zones 
outlined are shown in Figure 2.9C.  
 
2.8.3. Activation of Cardioprotective Pathways 
Cardioprotection by activation of the Akt-eNOS pathway. 
  To explore the effect of eNOS modulation on the regulation of known 
cardioprotective signaling pathways, we investigated the expression levels of 
phospho-AKT and phospho-eNOS in response to IR injury. Western blot analysis Page | 34 
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confirmed that phospho-Akt (p-ser473) and phospho-eNOS (p-Ser1176) protein 
levels increased in postconditioned WT mice (Figure 2.10A and 2.10B). Of interest, 
phospho-Akt protein levels were also increased in postconditioned eNOS ko mice, 
though this increase in expression did not result in increased tolerance against 
infarct size. While postconditioning has been shown to protect the myocardium 
through PI3K-Akt activation and phosphorylation of eNOS [70,  71]  we were 
interested its effects on Akt in S1176D ki mice. Compared with WT and eNOS ko 
mice, MIPc did not cause significant changes in phospho-Akt activity in S1176D ki 
mice.  
 
 
2.10 Postconditioning activates Akt and eNOS. (A and B) Representative Western 
blots demonstrating phosphorylated and total protein levels of Akt (Ser473) and 
eNOS (Ser1176) . Densities (in arbitrary units, AU) show that postconditioning 
phosphorylates Akt in WT and eNOS ko mice. Phosphorylated levels of Akt in 
S1176D mice are not affected by cardioprotective postconditioning. n = 5 per group. 
Data are expressed as the mean ± SD. * P < 0.05 
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2.9.  Discussion 
eNOS activity has been implicated in a wide range of cardioprotective 
signaling pathways including pre  and  postconditioning  [72-74], halogenated 
anesthetics [53], hydrogen sulfide [52] and statin [51, 75] therapies. In particular, 
eNOS S1176  can be phosphorylated by various kinases including Akt, AMP and 
protein kinase A and G, suggesting that S1176 phosphorylation may be a common 
integration point for multiple pro-survival signaling systems. In this chapter, we 
show that phosphomimetic modulation of eNOS S1176 confers protection against IR 
injury. The introduction of aspartate at the S1176 eNOS location mimics a gain-of-
function alteration which is associated with greater NO production due to increased 
electron flux through the eNOS reductase domain [28]. We confirm that basal levels 
of myocardial NO can be regulated by the degree of eNOS activity. The S1176D ki 
mouse model provides a valuable tool for exploring the therapeutic benefits of eNOS 
phosphorylation activity in protecting against IR injury.  
Using S1176D ki mice, we demonstrate that activated eNOS imparts 
profound tolerance against IR injury in vivo. It is notable that the reduction in infarct 
size in S1176D mice is comparable to that observed in postconditioned WT mice. 
Remarkably, when S1176D mouse hearts were challenged with IR we observed 
similar levels of protection regardless of the reperfusion method used. NO has been 
shown to mediate the inhibition of the mitochondrial permeability transition pore 
which has been strongly implicated in the progression of myocardial apoptosis Page | 36 
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resulting from IR injury [37, 76, 77]. The present data provide substantial support 
for the conclusion that increased eNOS phosphorylation protects the myocardium 
against IR injury.  
Previous studies have reported that postconditioning protects the 
myocardium through activation of the reperfusion injury salvage kinase (RISK) [78] 
and survivor activating factor (SAFE) pathways [79]. The RISK and SAFE pathways 
both phosphorylate eNOS at S1176  and are heavily implicated in ischemic 
postconditioning  [80]. Western blot data confirmed that phospho-eNOS and 
phospho-Akt activity are upregulated with postconditioning. Interestingly, phospho-
Akt activity is increased in eNOS ko mice although the infarct sparing effects of 
postconditioning are lost. This is in contrast to S1176D mice where phospho-Akt 
activity is left relatively unchanged in the presence of constitutively phosphorylated 
eNOS.  These results support the hypothesis that postconditioned protection against 
IR is induced directly through the phosphorylation state of eNOS. 
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2.10.  Materials and Methods 
Animals 
Knock-in mice carrying a S1176D (serine for aspartate) mutation in the endogenous 
eNOS locus were generated by homologous recombination. The TCT codon for 
Serine1176 in exon 26 of the native eNOS gene was replaced with GAT to produce a 
S1176D (aspartate) mutation. The targeting construct carrying this mutation in 
exon 26 was flanked by homologous regions on either side. A neomycin resistance 
gene flanked by loxP sites adjacent to the mutation allowed for positive selection. A 
thymidine kinase gene was incorporated at one end of the construct to facilitate 
negative selection, but was not incorporated into the final genome. The surrounding 
region of exon 26 was replaced with the mutated exon through homologous 
recombination. Mice were mated with EIIa-Cre transgenic mice resulting in excision 
of the neomycin resistance gene. Back-bred S1176D mice were compared with 
eNOS-deficient mice and C57BL6/J mice as controls. 
 
Nitric Oxide Assay 
The extent of baseline nitric oxide production in myocardial tissue was assessed 
using the commercially available flurometric assay  kit in accordance with the 
protocol supplied by the manufacturer (BioVision). The total concentration of nitrite 
and nitrate was used as a quantitative measure of NO production. Tissue samples 
were lysed for 10 minutes on ice with 300µl of tissue-lysis buffer. Tissue 
homogenates were centrifuged at 10,000g for 5 minutes at 4oC and further filtered 
through a 10kDa MW cut-off filter (BioVision) the filtrate was collected for the NO 
assay.  
 
In vivo Myocardial Ischemia Reperfusion Model 
Animals were anesthetized under pentobarbital sodium (50 mg/kg ip) and 
ketamine hydrochloride (50 mg/kg ip) anesthesia was maintained via supplemental 
doses (15 mg/kg ip) as needed. The depth of the anesthesia was monitored by tail 
pinch, constant monitoring of respiratory rate and heart rate. Mice were intubated 
with polyethylene 90 tubing (CWE) and connected to a Harvard respirator (Harvard 
Apparatus). The respiratory tidal volume was set at 1.0ml/min, and the rate was set 
at 120 strokes/min and supplemented with 100% oxygen.  Mouse left anterior 
descending coronary artery ligation was performed under through a thoracotomy 
performed left of the sternum to expose the pericardium. The pericardium was then 
visualized and opened and the left anterior descending coronary artery identified 
under stereo microscopy. A 7-0 silk ligature was passed underneath the vessel and 
through a custom snare to induce ischemia without damaging the artery. Ischemia 
was achieved by tightening the snare for 45 minutes and occlusion was confirmed 
by observed blanching of the anterior left ventricular wall. After 45 minutes the Page | 38 
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myocardium was reperfused with one of two algorithms 1) traditional myocardial 
ischemia-reperfusion (MIR) injury where the ligation was simply released or, 2) 
myocardial ischemia reperfusion with postconditioning (MIPc) where six cycles of 
10 sec reperfusion was followed by 10 sec of ischemia. After initiation of 
reperfusion, the chest cavity was then closed layer by layer. Buprenorphine HCl 
(0.05–0.1 mg/kg) was administered for post-operative care. The mice were 
monitored continuously for 6 h, then every 8 h and were treated according to IACUC 
guidelines if they appeared dyspneic or moribund. 
 
Infarct Size Determination 
At conclusion of the 24 hour reperfusion period, the LAD was religated with 7-0 silk 
suture, and 1ml of 1% Evans blue (Sigma-Aldrich) was perfused retrograde through 
a left carotid artery catheter the delineate the in vivo area at risk (AAR).  The heart 
was excised and fixed in a 2% solution of agarose gel and allowed  to solidify. 
Myocardial tissue was sectioned into 1-mm-thick axial sections using a McIlwain 
tissue chopper (Brinkmann Instruments). Infarct size was determined by staining 
with 2,3,5-triphenyltetrazolium chloride (TTC) (Sigma-Aldrich). and stained with 
2% TTC for 20 minutes in the dark at 37o C. Each sliced was weighted and visualized 
under a dissecting microscope equipped with a CCD video camera. The left 
ventricular area, AAR, and area of infarction for each slice were then determined by 
computer planimetry software. The final size of infarction was determined by 
integrating the infarct areas in each myocardial slice over the entire myocardium 
using a previously described equation [68]. 
 
Western Blot Analysis 
Myocardial tissues were harvested after 45 min ischemia and 10 min reperfusion. 
The left ventricular area at risk was isolated through visual identification of 
blanched myocardium during ischemia. Myocardial tissues were homogenized to 
obtain protein extracts and 100µg of protein was subjected to electrophoresis in 7% 
Tris-HCL polyacrylamide gels (Invitrogen). Proteins were transferred to PDVF 
membranes for western blot analysis and visualized by chemiluminescence 
(Amersham Biosciences) as previously described [64]. Antibodies to eNOS (Sigma-
Aldrich), phospho-eNOS (p-Ser1177 human sequence numbering, BD Bioscience), 
AKT (Cell Signaling) and phosphor-AKT (p-Ser473, Cell Signaling) were obtained 
commercially. 
 
Statistics 
All results are expressed as mean ± SD, except western blot densities which are 
expressed as mean ± SEM. Statistical analysis was performed in Matlab 
(Mathworks) using Kriskal-Wallis analysis of variance and Wilcoxon rank-sum tests 
with Bonferonni’s correction. Differences of P < 0.05 were considered significant. 
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Study Approval 
All experiments were conducted in accordance with the guidelines of the 
Institutional Animal Care and Use Committee (IACUC) of the Massachusetts General 
Hospital. Mice were euthanized according to the recommendations of the American 
Veterinary Medical Association Panel on Euthanasia.   
 
 
 
 
 
 
 
Chapter 3 
  In Vivo Quantification of Myocardial Blood Flow and 
No-Reflow Phenomena 
 
Endothelial dysfunction and no-reflow phenomenon can present as clinical 
complications after reperfusion. The degree of no-reflow in a patient has important 
prognostic value and is an independent predictive factor of patient prognosis and 
clinical outcome [81,  82].  While  experimental studies have established that 
pathologic myocardial blood flow deficits are propagated at the onset of 
reperfusion,  the role of eNOS phosphorylation in targeting specific mediators of 
myocardial blood flow and no-reflow phenomena remains unknown.  
The ability to measure myocardial blood flow over the dynamic time course 
of recovery  in vivo  would be scientifically  valuable but existing methods are 
impractical and limited in application by the small size of murine models. In this Page | 41 
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chapter we describe two different imaging modalities, Laser Doppler Flowmetry and 
Myocardial Contrast Echocardiography  (MCE),  and  evaluate  their  application  in 
measuring myocardial blood flow and no-reflow phenomena throughout the course 
of IR injury. We then apply MCE to our genetic mouse models of eNOS to investigate 
the role of phosphomimetic eNOS modulation on myocardial blood flow. 
 
3.1.  Motivation  
 
In the first part of this chapter we evaluate the effectiveness Laser Doppler 
flowmetry to measure myocardial blood flow. We outline the spatial limitations of 
laser  Doppler  and  its  inability to differentiate between core ischemic and 
prenumbral areas  of the ischemic myocardium.  Next, we describe the use of 
myocardial contrast echocardiography (MCE). MCE provides improved spatial 
resolution with the same ability to measure blood flow over time but motion of the 
myocardium during capture is problematic for analysis. In order to accurately 
identify the myocardium and track its location over time, we propose the use of an 
active contour image segmentation model guided by external gradient vector flow 
forces.  Our  image segmentation algorithm automates the characterization of 
myocardial blood flow and is capable of generating MCE replenishment curves for 
the purposes of analyzing myocardial blood flow. 
  In the second half of this chapter, we use MCE to study the effects of 
postconditioning on myocardial blood  flow.  Decreased vascular NO production Page | 42 
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results in the clinical manifestation of endothelial dysfunction, vascular wall 
inflammation and no-reflow phenomenon [83-86]. We extend our MCE studies to 
S1176D knock-in mice models and demonstrate the effectiveness of 
phosphomimetic eNOS modulation in improving blood flow following ischemia-
reperfusion injury.  Using the S1176D knock-in  mouse model, we determine the 
effects of ‘activated’ eNOS on myocardial blood flow using myocardial contract 
echocardiography (MCE). Our results demonstrate that enhanced eNOS enzymatic 
activity protects improves blood flow after myocardial IR. These results reveal the 
importance of in vivo  post-translational modification of eNOS in myocardial 
ischemic protection. 
 
3.2.  No-reflow Phenomenon 
The no-reflow phenomenon was first described by Kloner et al in 1974 when 
they reported reductions in blood flow in the infarct zone despite restoration of 
coronary arterial flow to the ischemic myocardium [87]. At least two mechanisms 
have been identified to cause no-reflow in the coronary vasculature: micro emboli 
formation and capillary  dysfunction  [15].  In the  former,  micro emboli  likely 
originate from the disruption of lipid rich vulnerable plaques when thrombolytic or 
percutaneous coronary intervention  (PCI)  is used to reestablish coronary blood 
flow. Improved PCI methods that utilize aspiration or thrombectomy have helped to 
minimize no-reflow lesions caused by micro emboli [88].  Page | 43 
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The later cause of no-reflow however, can be attributed to the detrimental 
repercussions of  reperfusion itself.  Capillary dysfunction due to tissue edema, 
endothelial disruption and plugging of the capillaries by neutrophil infiltration can 
be caused factors which are all promoted by coronary reperfusion. The generation 
of reactive oxygen species, hyper contracture of adjacent myocytes and activation of 
the mitochondrial permeability transition all contribute in part, to the development 
of the no-reflow phenomenon [89].  
Current treatments for the no-reflow phenomenon include the use of 
vasodilators. The use of adenosine yields benefits beyond vasodilation by lowering 
neutrophil count and improving endothelial  integrity  [90].  While  there is 
diminished basal NO release after reperfusion  which  promotes neutrophil 
adherence to the coronary endothelium [91], the use of nitric oxide donors has been 
shown to reduce myocardial necrosis and neutrophil accumulation  [92, 93]. In this 
chapter we investigate the role of eNOS phosphorylation on no-reflow phenomenon 
with the use of S1176D knock-in mice to test whether the increased bioavailability 
of NO improves no-reflow after reperfusion. 
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3.3.  Laser Doppler Flowmetry 
In order the study the role of reperfusion on vascular function we developed a 
method to measure tissue perfusion in the murine heart using Laser Doppler 
Flowmetry. The application of Laser Doppler imaging to measure tissue perfusion has 
been previously demonstrated in skin, renal, skeletal muscle  and cerebrovascular 
studies [94-96] but its application in the murine myocardium, which is subjected to 
significant motion, has not been investigated.  
Laser Doppler flowmetry provides information about blood flow by registering 
the Doppler shift in frequency of reflected monochromatic laser light [97]. In the past, 
LDF has been applied to static tissues not subjected to the same motion artifacts as 
the heart. In our hands, we provide evidence that laser Doppler flowmetry can be 
used for continuous real-time measurement of local myocardial perfusion in the 
beating murine heart [98]. To assess myocardial micro perfusion a laser Doppler fiber 
optic probe was attached to the myocardial surface on the left ventricular 
myocardium lying in proximity to the LAD and away from obvious large vessels using 
tissue glue.  Attachment to the surface of the myocardium resulted in a free floating 
fiber optic probe which moved in unison with the beating heart (Figure 3.1). Due to 
the flexibility of the optical fiber, we were able to acquire tissue perfusion 
measurements virtually free of motion artifacts [99].  
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3.1 Implementation of Laser Doppler Flowmetry on the murine myocardium. 
A) Schematic of fiber optic probe attachment. The laser Doppler probe is secured 
with tissue glue to the anterior epicardial surface. The location of the probe is place 
distal from the point of ligation to confirm changes in blood flow post ligation. B) 
Implementation of the ligation snare and fiber optic probe.  
 
 
 
In order to quantify vascular function and tissue perfusion following ischemia, 
we applied LDF to the epicardial surface of the left ventricle, distal from the location 
of LAD occlusion. Figure 3.2 depicts LDF measurements of myocardial blood flow 
after an ischemic event in mice undergoing distal LAD occlusion followed by abrupt 
reperfusion or postconditioned reperfusion.  This data demonstrates the ability to 
quantitatively measure the degree of tissue perfusion in vivo. The top panel depicts a 
drop in tissue perfusion at the onset of ischemia followed by abrupt reperfusion of the 
myocardium after 45 minutes  of occlusion. LDF also captures  the hemodynamic 
profile of postconditioned reperfusion which is depicted in the bottom panel, showing 
the ‘staccato’ occlusion/reperfusion cycles indicative of postconditioning. Page | 46 
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3.2  Blood flow profile measured with Laser Doppler Flowmetry. Myocardial 
blood flow measurements for traditional reperfusion (top) and postconditioned 
reperfusion with 6 cycles of 10sec each (bottom). The anterior myocardium was 
subjected to 45 minutes ischemia followed by reperfusion. 
 
However, we found that fidelity of the LDF signal depends critically on the placement 
of the fiber optic probe. Placement of the probe in the core ischemic region versus the 
non-ischemic prenumbra is often difficult and thus, we conclude that LDF has limited 
application when comes to quantifying the degree of myocardial blood flow deficit in 
IR injury. With this understanding we explored the use of MCE and its ability to 
provide added spatial information. 
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3.4.  Dynamic Imaging of Blood Flow: Myocardial 
Contrast Echocardiography 
 
Myocardial Contrast Echocardiography (MCE) is an ultrasound imaging tool 
used for the assessment of myocardial blood flow. Blood itself is not a good reflector 
of ultrasound but the microcirculation of the myocardium can be measured through 
infusion of echo-opaque microbubbles into the blood stream. These microbubbles 
average 1 – 3 µm in diameter and are small enough to pass through pulmonary 
capillaries and the myocardial microvascular bed. Upon sonication the 
microbubbles oscillate with predictive characteristics generating a measurable 
acoustic response [100, 101]. The infusion of microbubbles is useful in applications 
where added contrast and visualization of the myocardial vascular bed is desired. 
The venous administration of microbubbles has been shown to result in successful 
myocardial opacification [102-104] and is helpful in identifying regional perfusion 
deficits [105]. 
Circulating microbubbles in the blood provides increased backscatter 
signaling and additional enhancement of the myocardial border. Figure 3.3 
illustrates the improved contrast provided during parasternal long-axis imaging of 
the heart comparing MCE versus normal echocardiographic imaging  in mice  (a 
thoracotomy has been performed to minimize shadowing effects from chest wall.) 
Use of contrast microbubbles ensures that the endocardial border between the 
ventricular lumen and myocardium is easy to identify. It is important to note  Page | 48 
 
 
 
Chapter 3: In Vivo Quantification of Myocardial Blood Flow 
 
3.3 Myocardial Contrast Echocardiography. A) Schematic of parasternal long axis 
(PSLA) view of the myocardium, adapted from Lilly, 4th Edition, 2007  [106]. B) 
Normal PSLA echocardiographic view. C) Enhanced PSLA view with myocardial 
contrast echocardiography, the left ventricular lumen is labeled LV.   Page | 49 
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however  that contrast agents can cause imaging artifacts that manifest as 
shadowing of the posterior septum, this makes it difficult to accurately perform MCE 
analysis in the posterior region. In our study, analysis of myocardial blood flow is 
thus restricted to the anterior septal region. 
Because harmonic vibration signals emanate mostly from the microbubbles 
rather than tissue, selective reception of these signals provides an increased signal-
to-noise ratio, and opacification of myocardial tissue [100]. ‘Second generation’ high 
molecular weight gas filled microbubbles were used instead of air-filled 
microbubbles because the highly diffusible oxygen and nitrogen from air can leak 
out and dissolve into the blood. Our second generation microbubbles are made of 
Perflutren lipid microspheres (Definity, Lantheus imaging, Billerica, MA) composed 
of octafluropropane gas encapsulated in an outer lipid shell. Definity microbubbles 
are characterized by low solubility and high stability in the  blood. 
Octafluoropropane (empirical formula of C3F8) has a molecular weight of 188.  
Heavy gases are less soluble in blood and thus less likely to leak out of the 
microbubble to impair echogenicity. The high molecular weight of Definity 
microspheres  means  that the microbubbles generate high echogenicity  without 
large fluctuations in size. It is important for bubble size to remain constant because 
the backscatter of a bubble is related to the sixth power of its radius [107].  
While contrast enhanced ultrasound provides a useful tool for visualization 
of the endocardial border its ability to quantify myocardial blood flow is particularly Page | 50 
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valuable in our studies of IR injury. MCE measurement of myocardial blood flow is 
centered on  the ability of  ultrasound to induce microbubble destruction  and 
subsequent characterization of the rate of microbubble return. When microbubbles 
are subjected to high intensity ultrasound, destruction of microbubbles occurs 
causing the gas to escape, eliminating their echo-opaque properties. Microbubble 
destruction is dependent on the power output, ultrasound frequency and the 
duration of imaging. As the acoustic power of the ultrasound beam is increased, the 
microspheres move from a linear resonance response to a nonlinear harmonic 
oscillation response. At a critical threshold of power, fracture and destruction of the 
microbubbles occurs releasing the inert high molecular weight gas into the blood for 
clearance  [101].  More destruction occurs at lower transducer frequency, higher 
power output and increased imaging duration. Sonic cracking of microbubbles 
caused by high intensity ultrasound is shown in figure  3.4  below, when gas is 
released from the confines of the microbubble echo opacity is lost.  
 
 
3.4 Sonic cracking of a contrast microbubble.  (a-d)  Sonic cracking of a 4µm 
contrast bubble. (e-i) The gas is released from the perforated microbubble, 
reproduced from Postema et al. [100]. Page | 51 
 
 
 
Chapter 3: In Vivo Quantification of Myocardial Blood Flow 
Previous studies by Wei et al. have demonstrated that measurement of the rate of 
microbubble reappearance  after microbubble destruction provides a measure of 
myocardial blood flow [108]. Measurement of microbubble flow rate to estimate 
blood flow velocity is supported by findings from Jayaweera et al who reported a  
correlation between microbubble flow velocity and the mean transit rate of radio 
labeled red blood cells in dogs [109]. Another study conducted by Keller et al, 
working with hamsters, found that sonicated albumin microbubbles within the 
microcirculation accurately mimics red blood cell flow in the myocardium [110]. 
This concept is illustrated in figure 3.5 where a high energy ultrasound pulse has 
been applied to eliminate all microbubbles within the field of view. Once the 
microbubbles have been successfully destroyed the rate of microbubble 
replenishment within the ultrasound provides a measure of the microbubble 
velocity.  
In order to quantify myocardial blood flow two parameters are measured. 
First, upon destruction, measurement of the microbubble reappearance rate 
provides an estimation of the mean myocardial microbubble velocity. Second, the 
microbubble concentration (and subsequent ultrasound intensity) measured in the 
myocardium at steady state reflects the sum of the microbubbles in the myocardial 
cross-sectional area [108]. Together, myocardial blood flow can be calculated with 
knowledge of the mean myocardial microbubble velocity (ie. the rise parameter), β,  Page | 52 
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3.5 Method of quantifying mean myocardial blood flow. A) All microbubbles can 
be destroyed by a pulse of ultrasound at time t0. The thickness, E of the ultrasound 
beam causes destruction of all bubbles within that region. Then replenishment of 
microbubbles within that window can be measured (d1 through d4 with respect to 
time t1 to t4). B) The corresponding replenishment curve can be fitted to the inset 
equation  and  characterized  by  two  parameters,  blood  flow  velocity  (β)  and  the 
plateau blood volume, A. Adapted from Wei et al. [108]. 
 
 
 
and the myocardial microvascular cross-sectional area at steady state (ie. the 
plateau intensity), A. Using these principles in experiments with dogs with two-
dimensional echocardiography, Kaul et al concluded that measurement of the 
velocity of microbubbles through the myocardium accurately reflects myocardial Page | 53 
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blood flow [111]. Thus, MCE provides the unique ability to assess regional deficits in 
myocardial perfusion in vivo. 
Our study focuses on applying MCE to measure myocardial blood flow in a 
murine model of myocardial ischemia-reperfusion injury. Previous work on MCE in 
mice has been conducted by Scherrer-Crosbie et al [112] and Raher et al [113]. 
Implementation of  MCE in smaller mice models has a significant number of 
challenges including the need for smaller ultrasound transducers and the need to 
obtain and analyze replenishment curves from mice with fast heart rates in the 
range of 400-600 beats per minute. The fast heart rate limits the application of gated 
signal acquisition to EKG  recordings  because the acquisition frame rate of the 
ultrasound system (at  30 Hz)  would  omit important microbubble information 
during the replenishment phase. Video acquisition without EKG gating introduces 
significant myocardial motion into the MCE video frame. Consequently, analysis of 
murine MCE videos would be greatly aided by a robust image segmentation 
algorithm capable of identifying the endocardial and epicardial borders and able to 
generate  accurate replenishment curves despite significant motion of the 
myocardium.  
To  aid in  the quantification of myocardial blood flow from murine MCE 
videos we developed an image segmentation algorithm that utilizes active contours 
to detect and separate the myocardium from a contrast-enhanced ultrasound image.  
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3.5.  Active Contours for Image Segmentation 
Problem Objective 
Identification of the left-ventricular border from contrast-enhanced 
echocardiograms is essential for accurate quantification of myocardial blood flow. 
However, contrast replenishment curves must be obtained from MCE videos that 
contain motion artifacts caused by the periodic motion of respiratory and 
myocardial movement as well as external user produced motion  through 
manipulation of the ultrasound transducer. In this setting, manual identification of 
the ventricular border  can be slow and tedious  and  often susceptible to intra-
observer variability. Typical analysis requires manual identification and consistent 
segmentation across hundreds of video frames (300 frames in each MCE video). 
Therefore, in order to generate a reproducible replenishment curve, automated 
segmentation of the endocardial border is desirable to ensure consistency and limit 
the practical workflow. In this section, we present a tissue tracking algorithm that 
utilizes active contours to identify the left ventricle in videos obtained from MCE. 
Our attempt to automate detection of the left ventricle focuses on replicating 
human user based identification of edges. We are tasked with developing an image 
segmentation algorithm for a time series of two-dimensional echocardiographic 
images.  Analysis of MCE videos  for the purposes of generating microbubble 
replenishment curves requires that we first identify the myocardial borders and 
then track the course of its movement over time. Our tissue tracking algorithm takes Page | 55 
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advantage of the enhanced ventricular borders provided by constant infusion of 
Definity contrast agent. The epicardium and endocardium form the upper and lower 
boundaries of the left ventricle in the parasternal long axis view. The endocardial 
border is the curved boundary which separates the ventricular lumen from the 
inner myocardial surface while the epicardial border separates the outer surface of 
the myocardium from the pericardium and thoracic cavity. Together, the 
endocardial and epicardial borders define the ventricular tissue of interest.  
The endocardial border represents a promising geometric feature for image 
segmentation given the high degree of contrast between the two adjacent mediums 
[114, 115]. The high concentration of contrast agent in the ventricular lumen forms 
a distinct gradient boundary that we can utilize in the development of our active 
contours algorithm. Epicardial border detection is considerably more difficult 
because there is less differentiation in contrast between the epicardial surface and 
thoracic cavity. Detection of the epicardial border can be assisted by first identifying 
the endocardial border and then defining a typical distance between the endocardial 
and epicardial border. 
In summary, the resulting algorithm must be capable of wall motion tracking, 
account for the cardiac cycle (in the absence of EKG gating), background respirator 
movement and finally generate microbubble  replenishment curves from the 
segmented myocardium.  We employ a semi-automatic active contour model for 
detection of the endocardial border. Active contours represent a special case of Page | 56 
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general techniques that match a deformable spline to an image by means of energy 
minimization. The spline is influenced by constraining conditions and image forces 
that pull it towards object contours in an iterative fashion. To initiate border 
detection, an initial guess of the myocardial apex is placed on the image interactively 
by the user. The surface is then optimized or deformed to a new position in an 
iterative fashion guided by images features (ie. Edges) associated with the true 
endocardial border.  
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3.6 Image processing chain of myocardial contrast echocardiography image 
slices.  Processing of contrast ultrasound video consists of user defined 
identification of the myocardial apex and base followed by automatic active 
contours segmentation of the left ventricular volume. 
 
Active Contour Implementation 
Figure  3.6  depicts the data processing chain  used  for detection of the left 
ventricle. It consists of two distinct operations: user identification of the myocardial 
apex and base followed by automated  active contours image segmentation. 
Automated detection of the apex and base is hindered by acoustic interference from 
speckle noise and artifacts inherent in our ultrasound image, this makes consistent 
identification of the apex and base difficult and less reliable compared to human 
identification  [115].  Thus, user input is required in the first operation  because 
manual identification ensures proper location of the apex and base which is 
important for the generation of the initial spline. The apex of the left ventricle is the 
most anterior and inferior structure of the ventricular chamber while identification 
of the base is aided by alignment with the aortic root (in frame).  Page | 58 
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Once the apex and base have been identified, the image frame is cropped and 
converted to grayscale. A snake is then initialized between the apex and base to 
begin segmentation of the endocardial border.  A snake  is an energy minimizing 
spline guided by external constrain forces and influenced by salient features 
governed by the image, they are particularly apt at finding image contours such as 
edges, lines and terminals [116]. The snake is a curve that moves within the spatial 
domain of our image frame represented by, 
        ??(𝑠) = [𝑥(𝑠),𝑦(𝑠)]        (3.1) 
optimized by minimizing the energy functional, 
    𝐸 = ∫
1
2[𝗼|?? (𝑠)|2 + 𝗽|??"(𝑠)|2] + 𝐸𝐸𝑥𝑡𝑒𝑟𝑛𝑎𝑙 𝑆 (??(𝑠))𝑑𝑆.  (3.2) 
The energy functional  is governed by  internal  and external energy 
parameters. The internal energy is composed of a first order term that acts as a 
membrane and second order term that acts as a thin plate,  where α and β are 
weighting  parameters that control the snake’s tension and rigidity  [117]. The 
external energy function is derived from the MCE image, EExternal. Many different 
methods have been used to define the external force of the image, with each method 
taking a different approach to guide the path of the snake as it moves through an 
echocardiographic image.  
Hommoude [115] and Noble et al [118] review many of the active contour 
methods applied to the field of echocardiographic image segmentation. For instance 
Cohen et al modify the snake by adding balloon like behavior to give more stable Page | 59 
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results when snakes are initialized away from contours [119]. Chalana et al employ 
a multiple active contour model for cardiac boundary detection, pooling information 
from multiple frames because individual echocardiographic images can contain 
missing boundaries [114]. Mikic et al employ optical flow estimates [120]  and 
Hamarneh et al applied Principal Component Analysis to a frequency-based 
representation of the left ventricle [121].  
We employ an external force model established by Xu et al who compute the 
external force  as a diffusion of the gradient vectors from a gray scale image, termed 
gradient vector flow [122]. The particular advantage of gradient vector flow derived 
external forces is that it is insensitive to initialization of the snake, the snake can 
initially be inside, outside or across an object’s boundary and has a large capture 
range meaning that the snake can be initialized far away from the endocardial 
boundary. In our application, the external energy functional can be expressed as a 
weighted combination of several factors to attract the snake to different features in 
our image. The total image energy can be expressed as a weighted combination of 
variables, 
    𝐸𝐼𝑚𝑎𝑔𝑒 = 𝑤𝑙𝑖𝑛𝑒𝐸𝑙𝑖𝑛𝑒 + 𝑤𝑒𝑑𝑔𝑒𝐸𝑒𝑑𝑔𝑒 + 𝑤𝑡𝑒𝑟𝑚𝑖𝑛𝑎𝑙𝐸𝑡𝑒𝑟𝑚𝑖𝑛𝑎𝑙  (3.3) 
By placing emphasis on wedge we preferentially force attraction of the snake to the 
endocardial border in our image. The edge functional ensures that the snake is 
attracted to contours with large image gradients 
        𝐸𝑒𝑑𝑔𝑒 = −|∇𝐼(𝑥,𝑦)|2        (3.4) Page | 60 
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3.7  External image force. A) Greyscale image myocardial contrast 
echocardiography (MCE) frame. B) Edge functional computed from MCE image. C) 
Gradient vector flow image. D) External gradient vector flow forces superimposed 
on grayscale image. The gradient vectors guide the spline towards the endocardial 
border. 
 
When applied to an MCE image, the endocardial and epicardial borders are made 
apparent in Figure 3.7B. Calculation of the external force using gradient vector flow 
from the initial image results in generation of an external force field. The gradient 
vectors that direct the snake to the endocardial boundary are visible in Figure 3.7C. 
Figure 3.7D shows the external force field super imposed on an MCE image. Iterative  Page | 61 
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3.8  Snake movement towards endocardial border.  A) Greyscale image 
myocardial contrast echocardiography (MCE) frame. B) User identification of the 
apex and base enables initialization of a spline between two points. C) Guided by the 
external image forces, the spline iteratively converges on the endocardial border. D) 
Final segmentation of the endocardial border. 
 
 
movement of the snake through the external force field drives the active contour to 
clamp on the endocardial boundary. The movement of the snake through the MCE 
image is shown in Figure  3.8.  Finally, the left ventricle is segmented into three 
distinct regions composed of the apical anteroseptum, mid anteroseptum and basal 
anteroseptum (Figure 3.9). Of note, ligation of the LAD occurs at the intersection of 
the mid and basal anteroseptum while the apical anteroseptum is distal from the  Page | 62 
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3.9 Segmentation of the left ventricle. Following identification of the endocardial 
and epicardial borders, the left ventricle is segmented into three regions, the: apical 
anteroseptum (white), mid anteroseptum (blue) and basal anteroseptum (red). The 
snare forms a ligation around the left anterior descending coronary artery at the 
location of the arrow. 
 
 
ligation site and most prone to blood flow deficits during LAD ligation. Tracking of 
all three regions over  time enables  us to generate  replenishment curves  of  the 
microbubbles refilling the myocardium. Evaluation of distinct regions allows us to 
examine whether areas furthest away from the point of ligation develop the most 
significant blood flow deficits.  
  Estimation of myocardial blood flow from each region of interest was 
obtained by fitting the replenishment curve to an exponential function 
        𝑦 = 𝐴(1 − 𝑒−𝗽𝑡)         (3.5) 
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3.10  Myocardial contrast echocardiography replenishment curve. 
Replenishment curves (at baseline before ischemia )  of the apical anteroseptum 
(white), mid anteroseptum (blue) and basal anteroseptum (red). 
 
 
where y is the signal intensity, β is the slope of the curve and A is the plateau 
intensity [108, 113].  An example of replenishment curves derived from all three 
anteroseptal regions is shown in Figure 3.10. In this figure, MCE was applied at 
baseline before ligation of the LAD and all three regions have similar replenishment 
curves. The characteristics of these replenishment curves will be affected differently 
following ischemia-reperfusion injury. 
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3.6.  Results 
In this section, we use the active contours image segmentation algorithm to follow 
the dynamic time course of myocardial blood flow in mice subjected to IR injury. We 
test the hypothesis that both postconditioning and phosphomimetic eNOS 
modulation improves blood flow in the myocardium after reperfusion. 
 
Improved myocardial blood flow in S1176D mice after myocardial IR injury. 
  eNOS is an important biological regulator of many cardiac functions 
including myocardial perfusion, leukocyte-endothelial cell interaction, platelet 
adhesion/aggregation and no-reflow phenomena. Given the central role that NO 
serves in regulating blood flow, we hypothesized that phosphomimetic modulation 
of eNOS improves myocardial perfusion after IR injury. We performed myocardial 
contrast echocardiography (MCE) [113,  123]  on mice subjected to 45 min LAD 
ligation and reperfusion to assess whether improvements in myocardial blood flow 
could contribute to changes in infarct size.  
We obtained high quality two-dimensional parasternal long-axis videos of 
the myocardium to assess changes in blood flow following IR injury (Figure 3.11A). 
MCE was performed serially over the time-course of reperfusion to provide a 
temporal understanding of myocardial blood flow (MBF) deficit. Ligation of the LAD 
produced a predominantly antero-apical myocardial area at risk (Figure 3.11B).  Page | 65 
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3.11 Development of myocardial blood flow deficit over time. A) Representative 
myocardial contrast echocardiography images taken at baseline, B) the potential 
infarct area has no myocardial blood flow during ischemia and C) 30 minutes after 
reperfusion,  arrow: myocardial blood flow deficit in apical anteroseptum 30 
minutes post-reperfusion. RV: Right ventricle, RA: Right atrium, LV: Left ventricle. 
 
 
Upon reperfusion, myocardial perfusion was markedly impaired with 
perfusion defects noted in the anteroseptal wall and apex (Figure 3.11C). To 
quantify these observations, the anteroseptum was divided into three regions 
during analysis to capture the distinct blood flow deficits in each anatomic region. 
The three myocardial regions are outlined in Figure 3.12A: region 1) the basal 
anteroseptum (outlined in red), 2) the mid anteroseptum proximal to the ligation 
site (blue) and 3) the apical septum distal to the ligation site (black). The location of 
LAD ligation occurred at the intersection between the mid and basal anteroseptum 
with the majority of blood flow deficits found in the apical septum (region 3). No 
significant differences in myocardial blood flow were measured in the basal and mid 
anteroseptum regions. 
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MCE replenishment curves were computed from raw MCE videos of infused 
contrast agent and used to estimate the myocardial blood flow. Significant 
differences in myocardial blood flow between WT, S1176D ki and eNOS ko mice 
were found in the apex of the myocardium after 30 minutes  of reperfusion. 
Postconditioning significantly improved blood flow in WT mice while no 
improvements in blood flow were detected in eNOS ko mice (Figure 3.12B). 
Interestingly, S1176D ki mice displayed marked improvements in myocardial blood 
flow after IR injury with blood flow restored close to baseline values. The protective 
effects of postconditioning against IR injury were associated with increased levels of 
myocardial perfusion in the apical septum. 
To extend our understanding of myocardial blood flow deficit and recovery 
over time we measured the temporal dynamics of MBF changes using MCE. Figures 
3.12C-E show the relative blood flow in the apical septum for WT, S1176D ki and 
eNOS ko compared to perfusion values at baseline before the onset of ischemia. WT 
mice subjected to MIR reperfusion exhibited worsening MBF over time, whereas 
postconditioned WT mice displayed progressive improvement in MBF over time 
with significantly improved perfusion after 30 minutes. In contrast, 
postconditioning failed to improve myocardial blood flow in eNOS ko mice. 
Examination of MBF in S1176D ki mice showed a rapid return to pre-ischemic levels 
of perfusion. Prompt recovery of blood flow was observed at the onset of 
reperfusion where MBF levels showed robust recovery to baseline levels. The  Page | 67 
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3.12 Phosphomimetic eNOS modulation improves myocardial blood flow.  
 A) The left ventricular anteroseptum was divided into three regions of interest 
defined by the apical septum, mid anteroseptum and basal anteroseptum. B) 
Myocardial blood flow deficit, Aβ, in the apical septum 30 minutes after reperfusion. 
Postconditioning improves myocardial blood flow in WT mice while both S1176D 
mice groups exhibit improved myocardial perfusion. C) Normalized temporal 
myocardial perfusion profiles in the apical region for C57BL/6J D) eNOS knockout 
and E) S1176D knockin mice. Levels of myocardial blood flow were measured at 
baseline, ischemia, and (2, 10 and 30 minutes) after reperfusion. MIR: Myocardial 
ischemia with reperfusion, MIPc: Myocardial ischemia with postconditioning. n = 5 - 
6 per group. Data are expressed as the mean ± SD. * P < 0.05 
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temporal results of from MCE analysis support the notion that increased eNOS 
activity enhances myocardial perfusion after IR  injury. Mean arterial pressure 
(MAP) and heart rate (HR) was monitored throughout the course of IR  and no 
significant difference was found between groups, baseline levels of MAP were 70 ± 5 
mmHg with an average of 468 ± 30 bpm while MAP after 30 minutes of reperfusion 
were 42 ± 8 mmHg with an average HR of 453 ± 23 bpm  
    
 
3.13  Regional analysis of improvement in myocardial perfusion. 
Representative region specific replenishment curves 30 minutes post reperfusion. 
Segmentation of the left ventricular wall was divided into three regions: apical 
(black), mid antero (blue), and basal anteroseptal regions (red). Postconditioned 
WT mice and both S1176D IR mice groups exhibit improved apical perfusion vs. 
impaired perfusion (arrows).  
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To investigate regional improvement in myocardial perfusion after IR injury 
we studied myocardial blood flow characteristics by region. Figure 3.13  shows 
representative reperfusion curves obtained 30 minutes after reperfusion from the 
apical, mid and basal anteroseptum of the myocardium. Baseline reperfusion curves 
were similar across all three regions and across all three mice groups. These 
findings show that the baseline levels of myocardial perfusion are conserved when 
eNOS activity is modulated. However, following IR the reperfusion curves differed 
significantly between mice groups. WT mice treated with traditional reperfusion 
(MIR) developed significantly larger apical septal deficits compared with WT mice 
treated with postconditioned reperfusion. Postconditioned WT mice (MIPc) 
displayed improved replenishment curves. 
Both MIR and MIPc treated eNOS ko mice groups showed large apical deficits 
in post reperfusion blood flow confirming that postconditioning failed to improve 
MBF in eNOS ko mice. In contrast, S1176D mice showed robust tolerance against 
myocardial perfusion deficit after IR.  Replenishment curves from both S1176D 
reperfusion groups responded well to IR injury with minimal deficits in MBF. These 
data show that eNOS activity is crucial to augmenting blood flow in myocardial IR 
injury. Thus, myocardial perfusion may be involved directly or indirectly in 
increasing myocardial tolerance against IR. Page | 70 
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3.14 Effect of postconditioning and S1176D mutation on no-reflow zones. (A) 
Representative images 30 minutes  after reperfusion. Superimposed areas (blue) 
indicate regions with ≤20% residual blood flow. (B) Composite graph showing areas 
of the myocardium with  ≤20%  (black)  and  ≤30%  (white)  residual  blood  flow 
compared to preischemic baseline. MBF: myocardial blood flow. n = 5 - 6 per group. 
Data are expressed as the mean ± SD. * P < 0.05  
 
 
Assessment of myocardial no-reflow phenomena. 
To further support the conclusion reached through regional analysis of 
replenishment curves, we assessed the spatial extent of ‘no-reflow’ zones using MCE 
after 30 minutes of reperfusion. This technique provides a quantitative assessment 
of the functional damage to the micro-vascular bed; obstructed or dysfunctional 
capillaries prevent contrast microbubbles from entering these areas, resulting in 
perfusion defects characterized as no-reflow zones [83]. WT MIR and eNOS ko mice 
developed larger myocardial areas with severe blood flow reduction (≤20% blood Page | 71 
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flow calculated using a thresholding-paradigm) compared with WT treated with 
MIPc (Figure 3.14). Constitutively active eNOS activity in S1176D mice significantly 
improved residual blood flow. Collectively, these findings indicate that eNOS activity 
is crucial in protecting against myocardial IR injury. 
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3.7.  Discussion 
In this chapter we investigated whether modulation of eNOS activity affects 
myocardial blood flow and micro-vascular function. eNOS influences leukocyte-
endothelial interactions [58], platelet aggregation and adhesion [124]. It is possible 
that eNOS phosphorylation and the resulting increase in NO production influences 
the degree of blood flow after IR. Furthermore, in a previous study, we reported that 
S1176D mice exhibit increased sensitivity to acetylcholine in response to vessel 
relaxation studies [64]. We used the S1176D mice model to explore the potential of 
modulating eNOS serine1176  phosphorylation activity as a therapy against 
myocardial IR injury. The ability to measure MBF levels with MCE at baseline and 
reperfusion allows for the detection of differences in blood flow in response to 
ischemic challenge.  
In our model of IR, ligation of the LAD produces an area at risk 
predominantly focused towards the apex of the heart. We found that 
postconditioning improves myocardial blood flow in the apical septum of WT mice 
while these benefits are lost in eNOS ko mice. Furthermore, modulation of the eNOS 
serine1176 phosphorylation site markedly improves blood flow in the same region. 
No additional benefit of postconditioning in  the S1176 ki mice was observed 
suggesting that phosphorylation of eNOS reproduces the beneficial effects of 
postconditioning. These results are important because they demonstrate the in vivo 
effects of eNOS activity on microvascular function. In this regard, improved MBF and Page | 73 
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increased NO production through eNOS activation may contribute to the profound 
tolerance against IR injury found in protected hearts.  
We investigated whether postconditioning is an effective treatment for no-
reflow phenomena. Previous studies utilizing thioflavine S (a fluorescent marker of 
capillary perfusion) reported that postconditioning fails to improve no reflow after 
IR [125]. In the present study, we utilize MCE and report failure to improve no 
reflow in postconditioned WT mice. However, while postconditioning may not 
reduce the anatomic area of no reflow, additional insight can be gained about the 
degree of endothelial dysfunction from analysis of MCE replenishment curves. On 
one hand, postconditioning may not improve the absolute area of no reflow. On the 
other hand, we find that the postconditioning improves regional MBF, suggesting 
that postconditioning influences the degree of endothelial dysfunction. There were 
no hemodyamic differences between groups. Thus, although no reflow zone may not 
be significantly reduced, improved perfusion within the area at risk may be involved 
in increasing myocardial tolerance against IR. 
In summary, our results establish that phosphorylation of eNOS at serine1176 
is an important determinant of myocardial IR injury in mice. While NO availability 
may potentiate the activation of various pro-survival pathways our findings reveal 
that eNOS activity also regulates the degree of myocardial blood flow in IR injury. 
These insights into the effects of eNOS activity on myocardial perfusion in IR injury Page | 74 
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suggest that eNOS S1176  activation could play an important therapeutic role in 
myocardial survival.   
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3.8.  Materials and Methods 
Myocardial Contrast Echocardiography Studies 
MCE studies were performed as previously described [113]. Mice were anesthetized 
with intraperitoneal injections of pentobarbital sodium (50 mg/kg) and ketamine 
hydrochloride (50 mg/kg). Heart rate and blood pressure were monitored through a 
carotid catheter and recorded with a blood pressure analysis module in PowerLab 
(ADInstruments). A venous line was placed in the left jugular vein for constant 
infusion of microbubbles. 10% Perflutren lipid microspheres (Definity, Lantheus 
imaging, Billerica, MA) were diluted 1/10 in sterile saline and infused intravenously 
at 20µL/min. A thoracotomy was performed to provide unobstructed visualization 
of the myocardium. A 7-0 silk suture was passed underneath the LAD and through a 
custom snare. MCE was performed with a linear transducer (14MHz; Acuson 
Sequoia C512 system, Siemens) using a mechanical index of 0.24. Perfusion images 
were obtained in real time following destruction of microbubbles using a sequence 
of 10 high-energy frames (mechanical index 1.9). Signal intensity was obtained for 
10 seconds after the high-energy sequence at a frame rate of 30 Hz. Parasternal 
long-axis views were required at the level of the aortic arch. For temporal 
monitoring of myocardial blood flow MCE was used to measure blood flow at 
baseline before ischemia, during ischemia, and at 5, 10, 30 minutes after initiation of 
reperfusion. 
 
Myocardial Perfusion Analysis 
MCE was performed on the anteroseptal wall in the parasternal long-axis view using 
methods previously described [113]. Detection and segmentation of the left 
ventricular anteroseptum was accomplished using a shape based snake model of 
edge detection in Matlab (Mathworks) [116, 126]. The anteroseptum was divided 
into three regions of interest defined by the apical septum, mid anteroseptum and 
basal anteroseptum. Average signal intensity within each region of interest was 
measured in each frame and a curve of signal intensity over time was fitted to an 
exponential function: 𝑦 = 𝐴(1 − 𝑒−𝗽𝑡), where y is the signal intensity, β is the initial 
slope of the curve and A is the signal plateau intensity. Two to three curves were 
averaged per time-point for each animal. Myocardial blood flow (MBF) was 
estimated by the product of Aβ. Values are expressed as percentage of baseline Aβ. 
 
No-reflow Analysis 
Myocardial contrast echocardiography measurements were taken at baseline as a 
measure of myocardial blood flow before ischemia and compared against MCE 
measurements taken at the end of the study, 30 minutes after reperfusion. Three 
consecutive MCE images were averaged for each animal under each condition, the 
average signal intensity of the left ventricular anteroseptum at baseline was Page | 76 
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calculated. Images were converted to relative myocardial blood flow images by 
using a thresholding paradigm to identify areas of severe (0%-20% residual blood 
flow, representing the core ischemic region) and moderate (21%-30% residual 
blood flow, representing penumbra) blood flow relative to baseline [127]. 
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  In Vivo Quantification of Infarct Size 
 
Molecular biomarkers can be used as objective indicators of pathologic 
processes. Although their levels often change over time, their measurement is often 
constrained to a single time point. Cumulative biomarker exposure would provide a 
fundamentally different kind of measurement to what is available in the clinic. In 
addition,  in vivo  monitoring of MI biomarker levels over time may have useful 
applications in basic research. In small  animals models of myocardial IR injury 
where serial blood draws are not feasible, the ability to measure myocyte cell death 
overtime in a single animal would provide valuable information. The current gold 
standard for evaluating infarct size in small animals prohibits this type of analysis Page | 78 
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because existing methods rely upon gross-anatomical staining and end stage 
sacrifice of the animal. In our hands, the ability to obtain cumulative biomarker 
measurements would enable us to evaluate the efficacy of cardioprotective 
therapies in genetic mice models of myocardial IR injury. 
Magnetic resonance relaxometry can be used to noninvasively monitor 
changes in the relaxation properties of antibody-coated magnetic particles when 
they aggregate upon exposure to a biomarker of interest. We report in this chapter 
on implantable devices containing such sensors that continuously profile changes in 
three clinically relevant cardiac biomarkers at physiological levels for up to 72 h. 
Sensor response differed between experimental and control groups in a mouse 
model of myocardial infarction and correlated with infarct size. Our prototype for a 
biomarker monitoring device also detected doxorubicin-induced cardiotoxicity and 
can be adapted to detect other molecular biomarkers with a sensitivity as low as the 
pg/ml range. 
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4.1.  Motivation 
 
   The physiological levels of molecular biomarkers can be regarded as time-
varying continuous signals. However, clinicians seldom take advantage of this 
temporal information in making diagnostic and prognostic decisions. Biomarker 
measurements are often made at single time points, which do not adequately 
capture the dynamics of the underlying signal if they miss transient changes 
occurring between measurements. For instance, levels of serum cardiac troponin I 
(cTnI), creatinine kinase (the CK-MB isoform) and myoglobin elevate and return to 
baseline in a stereotyped manner after acute myocardial infarction (MI). The 
earliest rising biomarkers are myoglobin and the CK-MB isoform which rise to a 
peak of 2 to 5 times the upper limit of normal range following acute MI (Figure 4.1) 
[128]. Cardiac troponin is currently the preferred clinical biomarker for diagnosing 
myocardial infarction and troponins can rise 20 to 50 times about the normal limit 
in the setting of large infarctions [129]. The length of time in which the biomarkers 
remain elevated about the upper limit of normal also varies, with myoglobin and 
CK-MB exhibiting more transient characteristics and troponin exhibiting extended 
levels of elevation  in serum. Thus, a given measured value could correspond to 
either the early or late phase of biomarker release.  
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4.1  Timing release of cardiac biomarkers after acute ischemic myocardial 
infarction.  The cardiac biomarkers myoglobin, CK-MB and troponin exhibit 
increased serum concentration after acute myocardial infarction. While myoglobin 
and CK-MB levels are the earliest to rise they  typically return to normal range 
within 2 to 3 days, troponins can rise and stay elevated for 7 days or more. The 
horizontal dashed line shows the upper limit of normal range (defined as the 99th 
percentile from a normal reference population), adapted from [128]. 
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Here we describe implantable magnetic relaxation sensors that are capable 
of integrating biomarker levels over time. The signal from such a device 
corresponds to the entirety of biomarker release long after a pathologic event has 
occurred, and even after the concentrations have returned to baseline. 
Most MIs are characterized by symptoms of severe discomfort. However, a 
significant minority, defined as unrecognized MIs, are accompanied by minimal or 
no symptoms. The 30-year follow-up of the Framingham Heart Study reported that 
28% and 35% of MIs are unrecognized in men and women, respectively  [130]. 
However, current standards for detecting unrecognized MIs rely primarily on elec-
trocardiographic surveillance. Results vary markedly between such studies because 
of differing electrocardiographic criteria  [131,  132]. Patients at high risk for 
unrecognized MIs are followed periodically by their cardiologists but  MIs timed 
between these visits can go unnoticed. A sensor that reports on integrated MI 
biomarker levels throughout these intervals could therefore be used to identify 
these previously undetectable infarcts. 
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4.2.  Magnetic Relaxation Switch Sensors 
 
 A new class of nanoparticle-based magnetic resonance contrast agents 
makes this type of application feasible. Superparamagnetic iron oxide nanoparticles  
aggregate about analyte molecules and alter the transverse relaxivity (T2) of 
surrounding water protons  [133-137]. Dubbed magnetic relaxation switches 
(MRSw), the particles can be functionalized to detect a variety of small molecules 
including proteins, nucleic acids, oligonucleotides, peptides, receptors, ligands and 
antibodies  [137-143].  Our strategy incorporates primary to secondary antibody 
binding for specific detection of cardiac biomarkers. The antibody functionalized 
superparamagnetic nanoparticles aggregate in the presence of specific cardiac 
biomarkers changing the T2 time of the aqueous solution when interrogated with 
magnetic resonance analysis (Figure 4.2).  
Incorporation of these agents into implantable sensors permits noninvasive 
biomarker measurements using magnetic resonance relaxometry. We constructed 
small discrete sensors incorporating MRSw technology to measure cardiac 
biomarkers and characterized their performance in vivo in a murine model of MI 
characterized by the release of three clinically validated biomarkers at physiological 
concentrations. MI detection is particularly well matched for MRSw technology as 
MI size, a clinically relevant feature, is expected to correspond to cumulative 
biomarker release. A previous effort to explore the in vivo efficacy of similar sensors 
was fundamentally limited by the lack of correspondence between naturally  Page | 83 
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4.2  Magnetic resonance switch (MRSw) activation. Superparamagnetic iron 
oxide nanoparticles (black) are functionalized with polyclonal antibodies (red and 
yellow). Magnetic relaxation switching occurs in the presence of biomarkers (blue) 
which decreases the transverse relaxivity (T2) of surrounding protons. The 
subsequent signal can be detected using magnetic resonance relaxometry, adapted 
from [129]. 
 
occurring cancer and the xenograft tumor model used; the xenograft tumors 
released biomarkers at concentrations significantly above, and in a temporal fashion 
that did not resemble, that of physiological tumors [144]. 
Myoglobin, cTnI and CK-MB are functional proteins released by the ischemic 
myocardium after an acute infarct. Their serum dynamics are well known in 
humans: whereas levels of myoglobin rise and fall rapidly over 24 h after MI, levels 
of cTnI and CK-MB can remain above baseline for up to a week [145]. We adapted a 
left anterior descending (LAD) artery ligation procedure, as described  [146], to 
experimentally induce acute myocardial infarction in C57BL6 mice. Page | 84 
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4.3.  Extravasation of Cardiac Biomarkers 
 
 
   The sensors were designed to sample biomarkers in a potential  space 
created within the animal. If in situ sensing is to be achieved, the intended cardiac 
targets traditionally measured in serum (Figure  4.3) must be detectable in the 
location of sensor implantation. Serum levels of cardiac biomarkers after acute MI 
are well characterized in the existing literature [147], but their extravasation to the 
potential spaces  had not previously warranted study. We evaluated the 
effectiveness of two potential spaces by determining the extravasation dynamics of 
cardiac biomarkers into the peritoneal space and a subcutaneous space created in 
the flank. The time course of cardiac biomarkers after MI in the serum and 
peritoneum were evaluated (Figure  4.4).  We document a peritoneal ‘lag’ in 
myoglobin concentration and the absence of TnI.  These results indicate that the 
peritoneal space is a poor environment for sensor implantation. 
Next, we experimentally determined the extravasation dynamics (Figure 4.5) 
in the subcutaneous flank region under three conditions: MI, sham and control. 
Whereas MI groups received sensor implantation, thoracotomy and LAD ligation, 
sham groups received sensor implantation and thoracotomy but no LAD ligation. 
Control groups received sensor implantation only.  
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4.3  Murine cardiac biomarker serum  dynamics following acute myocardial 
infarction. cTnI, myoglobin and CK-MB serum profiles after LAD ligation are within 
the range of literature results and confirm the validity of the MI model used. 
Approximately 0.5 ml of blood was drawn from each subject, the serum extracted by 
centrifugation and biomarker levels measured by ELISA at the indicated times after 
LAD ligation. Results are averages (n = 4). 
 
 
 
 
 
4.4  Cardiac biomarker peritoneal space extravasation dynamics. ELISA 
measurement of cardiac biomarkers in the peritoneal space demonstrates a 
significant myoglobin ‘lag’ and the absence of troponin. The peritoneal space 
represents a poor implantation site for cardiac biosensors. 
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These results confirm that the subcutaneous flank space is a viable site for 
cardiac  biomarker detection, as biomarker elevations in the MI group differed 
significantly (P < 0.05) from the sham and control groups. It should therefore be 
possible to distinguish between the experimental conditions based on measure-
ments acquired from implanted sensors. There are, however, some initial elevations 
in myoglobin and CK-MB for the control and sham groups that we would expect the 
sensors to detect. Open chest surgery and subcutaneous device implantation cause 
substantial noncardiac injury. The early behaviors of these biomarkers are 
consistent with their differing specificities for cardiac injury; cTnI is highly specific 
to cardiac damage, but CK-MB is less specific and myoglobin is a marker of general 
muscle damage. That myoglobin and CK-MB are elevated in the control groups 
(Figure 4.5b,c, green) suggests local implantation-induced trauma will be visible to 
the implanted sensors. No significant difference can be found between the sham and 
control groups for any  biomarker, suggesting that thoracotomy-induced trauma 
should not affect the in situ sensor response. 
The movement of protein biomarkers from the circulation to the 
subcutaneous space should depend on the chemical properties of the specific 
biomarker as well as the vascularization and morphology of the implant site. The 
reliability of subcutaneously implanted sensors may be limited by these factors. 
Nonetheless, there is little delay seen here between the peaks in the accumulation of 
serum (Figure 4.3) and extravasate (figure 4.5) biomarkers. Page | 87 
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4.5 Cardiac biomarker flank space extravasation dynamics. Three experimental 
conditions  were imposed: control (sensor implantation only), sham (sensor 
implantation and thoracotomy only) and MI (sensor implantation, thoracotomy and 
LAD ligation). Each biomarker extravasates, with MI groups exhibiting significantly 
elevated concentrations, as compared to the corresponding control and sham 
groups. Presumably, implantation-induced injury caused the low initial cTnI in the 
setting of high initial myoglobin and CK-MB. The similarity between sham and 
control groups indicates that any thoracotomy-induced biomarker release is not 
significantly 'visible' in the sensor implant site. Extravasate samples were obtained 
by flushing the flank with 1 ml PBS at the indicated times after LAD ligation and 
measured using ELISA. Values are normalized within each panel to the maximum 
measured concentration. Results are averages ± s.e.m. (n = 4, normalized); P < 0.05 
is indicated by black asterisks between MI/sham, red asterisks between MI/control 
and green asterisks between sham/control. Page | 88 
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Rapid subcutaneous availability of these biomarkers, coupled with a 
sufficiently rapid sensor response, should enable potential applications of MI 
detection using this technology. The samples were obtained by flushing the 
subcutaneous space with 1 ml PBS and were assayed by enzyme-linked immuno-
sorbent assay (ELISA). We considered these measurements a first-order 
approximation of biomarker extravasation and used them as a checkpoint for 
proceeding with sensor implantation. 
 
4.4.  Biomarker Dosimeter Characterization 
 
To engineer discrete sensors containing appropriately functionalized MRSw 
nanoparticles, we enclosed particles in the reservoirs by size-exclusion membranes 
(Figure 4.6). The dynamic range of each sensor was tuned by adjusting the device 
transport characteristics and the nanoparticle chemistry. Careful selection of the 
membrane composition, pore size and surface area permitted control of analyte 
transport into the device. cTnI sensors were tuned for sensitivity in the 10–100 
ng/ml range, whereas sensors to detect myoglobin and CK-MB were tuned to detect 
in  the  100  ng/ml  to  1  μg/ml  range  to  reflect  the  expected  subcutaneous  levels 
(Figure 4.7). 
Antibody-antigen binding can provide an extremely strong noncovalent 
interaction. We tested the proposition that antibody-based MRSw sensors would be  Page | 89 
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4.6 Biosensor design. The sensor consists of a reservoir containing MRSw particles 
enclosed by a size-exclusion membrane. T2 changes are produced when analytes 
diffuse across the membrane and initiate particle aggregation.  The sensor is 
designed for implantation into the  subcutaneous flank,  images courtesy of Ling 
[148]. 
 
 
irreversible and that the degree of T2 change would correspond to the cumulative 
analyte exposure. The sensors were exposed to four different constant myoglobin 
concentrations (Figure  4.8A) to investigate the integrative capacity of antibody-
based MRSw. The overall response rate is proportional to the concentration outside 
the device, demonstrating that the sensor behavior is dominated by diffusion  Page | 90 
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4.7  Biosensor calibration in vitro. Sensor response as a function of analyte 
concentration was calibrated to match expected in vivo  concentrations. The 
measurements were acquired after an incubation time of 72 h for cTnI and 24 h for 
myoglobin and CK-MB sensors to match the expected duration of elevation for the 
respective biomarkers. Results are averages ± 95% confidence intervals (n = 4). 
 
transport into the device reservoir. We define exposure as  ∫
=
=
m t
t
m dt t C t E
0
) ( ) ( , 
where C(t) is the analyte concentration as a function of time and tm is the time of 
measurement. Plotting the measured T2 against exposure yields a single curve that 
is independent of the analyte concentration and verifies that the sensors operate as 
dosimeters in a diffusion-limited regime (figure 4.8B, solid and dotted lines). The 
diffusion occurs across the full area of the device reservoir and the devices saturate 
at ~1.5 μg·h/ml. The saturating exposure level can be tuned to the anticipated in 
vivo biomarker levels by adjusting the area available for diffusion. Reducing the 
diffusion area by half would, therefore, increase the saturating exposure by a factor 
of two.  
We next studied sensor response to three time varying concentration profiles 
as shown in Figure 4.8B (inset) (n = 2) because physiologic biomarker levels often Page | 91 
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follow nonconstant dynamic patterns. These profiles simulate transient biomarker 
release when the instantaneous biomarker concentration at the time of 
measurement is zero. The sensor signal persists after the analyte is no longer 
present, and the measurements (Figure 4.8B, red/blue/green data points) coincide 
with the measured T2 versus exposure profile (Figure 4.8B, solid and dotted lines). 
The results from prolonged exposure to constant and transient concentration 
profiles indicate that the biosensors ultimately function in a manner analogous to 
radiation dosimeters; they report  consistent  T2  changes independent of the 
biomarker exposure profile. 
The measurement of cumulative analyte release could be useful in detecting 
biomarker concentrations that are below the level of detection of blood-draw 
assays. This property also limits antibody-functionalized MRSw to fixed lifetimes 
reached when the binding sites are saturated. Cumulative sensors can thus only be 
used for finite durations, necessitating careful engineering of the particles and 
devices to match the chosen application’s required sensitivity and lifetime. 
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4.8  Cumulative exposure to analyte in vitro. A) Characterization of sensor 
saturation with exposure to constant concentration profiles. Devices were 
maintained in a constant concentration of myoglobin solution and the relaxation 
time  T2  was measured every 20 min. The time to saturation depends on the 
concentration. All of the devices, with the exception of the control, show a similar 
response and saturate at the same T2 value. The total exposure of the device to 
myoglobin  (measured  in  units  of  [μg·h/ml])  is  defined  as  the  area  under  the 
concentration versus time curve up until the measurement time. B) Exposure to 
constant and temporal concentration profiles demonstrate that MRSw sensors 
function as dosimeters. Plot of T2 versus the constant exposure profiles obtained 
from  e  are shown as curves. The symbols represent the average T2  of devices 
exposed to various temporal concentration profiles shown inset. The curves and 
symbols lie on top of each other, demonstrating that the response depends 
exclusively on exposure. Most points have deviations smaller than the symbol size. 
Measurements were made after several hours of incubation at zero concentration. Page | 93 
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4.5.  In Vivo Validation 
 
We proceeded to implant subcutaneous sensors specific for each biomarker 
in the flanks of animals from the MI, sham and control groups. It is possible that the 
sensors might be acutely exposed to intravascular fluid as a result of surgery-
induced capillary disruption. Sensors in all three (MI, sham, control) groups were 
therefore implanted before any further surgery so that their acute post-implant 
exposures did not vary between groups. Any differences between the three groups 
can therefore be attributed to true biomarker extravasation.  In situ MRI 
measurements demonstrated that the sensors can be interrogated at the implant 
site (Figure 4.9).  
 
4.9 MRI interrogation of implanted biosensors. A T2 map (color bar on the right) 
superimposed on T2  -weighted images of myoglobin sensors demonstrates the 
feasibility of MRI-based in situ measurements after 24 h implantation with (MI) or 
without (control) concomitant LAD ligation at the time of sensor implantation. The 
images show that the sensors can be measured in either the axial or the transverse 
plane. Page | 94 
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Most measurements were obtained from explanted sensors using a single-sided 
relaxometer. Despite the limited sensitivity of the single-sided system, T2 increases 
of the MI over the sham and control groups for all three biomarkers are evident 
(Figure 4.10). Wilcoxon rank-sum two-sided tests give significant P values (P < 0.05) 
for cross comparisons between the MI and control groups, and between the MI and 
sham in levels of myoglobin and CK-MB above baseline in the sham and control 
groups reflect noncardiac injury caused by the initial surgical procedure. Implanted 
MRSw sensors functionalized against IgG alone showed negligible increases in T2. 
 
4.10 Sensor response differs markedly between MI and sham/control groups. 
The T2 of explanted sensors, as measured by single-sided proton relaxometry (after 
72 h implantation for cTnI and 24 h for myoglobin and CK-MB), from the MI group 
are significantly higher (* indicates P < 0.05 using the Wilcoxon rank-sum two-sided 
test) than from the control/sham groups for all three biomarkers. Increases in the 
T2  of myoglobin and CK-MB sensors for both control and sham groups were 
expected and consistent with the extravasation results. Results are averages ± 95% 
confidence intervals (n = 36; 6 sensors/subject and 6 subjects/group). Page | 95 
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The infarct zone can be visualized through 2,3,5-triphenyltetrazolium 
chloride staining and objectively quantified as the fraction of left ventricular volume 
[149]. The cumulative release of cardiac biomarkers should be directly proportional 
to the magnitude of infarction, as the biomarkers are functional proteins directly 
released from the ischemic tissue. A comparison of sensor readings with infarct size 
(Figure  4.11) shows a consistent trend for all three biomarkers, despite the 
relatively large errors. The capability to quantitatively measure infarct size has 
important implications for risk stratification of MI patients [150, 151]. This factor, 
usually measured indirectly in the clinic through functional tests or imaging, can be 
directly quantified by the implantable sensors described here. Page | 96 
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4.11  Biosensor correlation with ex vivo infarct size. T2  change of the same 
explanted sensors from figure 4.10, if disaggregated into the individual subjects and 
replotted as a function of infarct size, correlates positively with infarct size for all 
three cardiac biomarkers. The cumulative release of biomarkers from the infarcted 
myocardium generates the final T2 sensor value. This characteristic may contribute 
to the correspondence between sensor reading and infarct size. Results are averages 
± 95% confidence intervals (n = 6 sensors/subject). Page | 97 
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4.5.1. Cardiotoxicity 
 
We further studied application of the sensors to discern drug cardiotoxicity. 
Doxorubicin is a potent anthracycline antibiotic that has found wide clinical use as a 
cancer chemotherapeutic [152, 153]. Its cardiotoxic effects are well known; after 
administration, patients exhibit dose-dependent loss of cardiac myocytes 
accompanied by serum cardiac biomarker elevation [154]. We confirmed that serum 
myoglobin increases after doxorubicin administration in a murine model (figure 
4.12A), although at an order of magnitude lower concentration than after acute MI 
(102 ng/ml versus 103 ng/ml). Myoglobin sensors were thus left in vivo for 72 h 
after implantation (as opposed to 24 h for acute MI). The results show a clear 
distinction in sensor T2  between the experimental and control groups, thus 
validating sensor efficacy in assaying drug cardiotoxicity (Figure  4.12B). These 
sensors may potentially be used in the future to establish the cardiac side effects of 
novel pharmaceuticals. 
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4.12 An implanted MRSw sensor device can detect the cardiotoxic effect of the 
chemotherapeutic drug doxorubicin in vivo. A) Doxorubicin induces a significant 
(* indicates P < 0.05) increase in serum myoglobin (ELISA measurements). Results 
are averages ± 95% confidence intervals (n = 4). Wilcoxon rank-sum two-sided tests 
were used to test for statistical significance. B) Myoglobin sensors explanted (after 
72 h) from a doxorubicin-administered group show significant increases in T2 over 
those from a control group. Results are averages ± 95% confidence intervals (n = 16; 
4 sensors/subject and 4 subjects/group). 
 
 
4.6.  Discussion 
 
New high-sensitivity troponin assays will lead to an increasing population of 
patients identified with elevated troponins of nonischemic etiology. Additional 
assays will need to be developed to help physicians distinguish between acute 
coronary syndromes and other causes. In vivo diagnostic MRSw measurements may 
prove to be especially useful in discriminating between troponin elevations caused 
by transient tachyarrhythmias and sustained ischemic episodes. These integrative Page | 99 
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sensors are engineered to have lower sensitivity so that they do not saturate upon 
total exposure to analyte released during and after an MI. The troponin sensor 
discussed here, for example, has  sensitivity in the ng/ml range but could be 
engineered for even higher sensitivity to the pg/ml range of the newest troponin 
assays. Thus, integrative sensors may provide prognostic value as sentinels in high-
risk patients and for the detection of unrecognized MIs. The ability to track 
cumulative biomarkers in vivo can be advantageous for its ability to capture 
transient events, which are frequently missed with serial testing. Furthermore, this 
type of sensor can be useful in research as a tool for monitoring biomarkers in small 
animals in which serial blood draws may not be feasible. MRSw can be 
functionalized to detect a variety of small molecules and further study will establish 
the general efficacy of these sensors. The sensors require single time point 
measurements that fit comfortably into the traditional clinical paradigm because 
they are practical to obtain, yet provide information on biomarker levels from the 
time of sensor implantation to when accumulation is measured. We have shown the 
utility of  cumulative biomarker measurements for applications relevant to heart 
disease. Such data will in all likelihood prove to possess clinical value for other 
applications as well. The MRSw molecular sensors described here represent a 
possible path in that direction. We showed that they perform adequately in the 
detection of pathologically elevated levels of three soluble disease biomarkers that 
extravasate from the circulation to the implant site. They are stable over several Page | 100 
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months and can be applied as disease sentinels in MI patients at high risk for short-
term recurrence.    Page | 101 
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4.7.  Material and Methods 
Preparation of magnetic nanosensors.  NanoMag-CLD SPIO nanoparticles (50 nm) 
with amine terminated dextran shells (Micromod) were coupled with monoclonal 
antibody against goat IgG  (Meridian Life Sciences, Saco, ME) using a previously 
described method 25.  These particles were then derivatized against specific targets 
by incubation with goat-produced polyclonal antibodies against cTnI (BiosPacific, 
Emeryville, CA), myoglobin (BiosPacific, Emeryville, CA) and CK-MB (BiosPacific, 
Emeryville, CA).  Unless otherwise specified, particles were suspended in PBS with 
1% bovine serum albumin (Sigma-Aldrich, St. Louis, MO) and 0.1% penicillin-
streptomycin (Invitrogen, Carlsbad, CA) to minimize bacterial contamination and 
non-specific adsorption.   
 
Device fabrication and implantation.  Derivatized particles were encapsulated 
within small diffusion devices 15.  Polycarbonate diffusion membranes (SPI 
Supplies, West Chester, PA) were affixed by double-sided adhesive to one side of 
high density polyethylene cylinders (thickness = 1.6 mm, inner diameter = 4.1 mm, 
outer diameter = 7.9 mm).  The opposing end was closed off by single-sided 
adhesive (3M) after the reservoir was filled with 25 μL particle solution.  Devices (n 
= 6 per animal) were implanted subcutaneously in the flank.  The animals were 
sacrificed and the devices explanted for single-sided relaxometry at specified time 
points.  Devices were sealed with single-sided adhesive and replaced in the implant 
site for imaging.   
 
Myocardial infarction surgery.  All experiments were conducted in accordance with 
the guidelines of the Institutional Animal Care and Use Committee (IACUC) of the 
Massachusetts General Hospital. Mouse LAD ligation has been previously described 
17. The procedure was performed under 2% isoflurane anesthesia with 
supplemental oxygen. The depth of the anesthesia was monitored by tail pinch, 
constant monitoring of respiratory rate and heart rate. An intercostal approach 
between the 3rd and 4th intercostal spaces was taken to expose the pericardium.  
The pericardium was then visualized and opened and the LAD identified under 
stereo microscopy.  A silk ligature was passed underneath and tied around the 
vessel to induce occlusion.  Occlusion was confirmed by observed blanching of the 
anterior left ventricular wall.  The chest cavity was then carefully closed layer by 
layer.  Sham-operated mice underwent the same procedure without tying the LAD 
ligation suture. Buprenorphine HCl (0.05-0.1 mg/kg) was administered for post-
operative care. The mice were monitored continuously for six hours, then every 8 
hours and were treated according to IACUC guidelines if they appeared dyspneic or 
moribund. 
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Independent measurements of biomarker levels.  Commercially available enzyme-
linked immunsorbent assays were used to independently quantify Myoglobin (Life 
Diagnostics, West Chester, PA), CK-MB (Oxis International, Foster City, CA), and 
Troponin I (Life Diagnostics, West Chester, PA) levels following control, sham and 
MI Procedures.  Each kit was strictly used in accordance with included instructions.  
Extravasate samples were obtained by flushing the flank with 1 mL PBS at the 
indicated times after LAD ligation. Doxorubicin cardiotoxicity biomarker levels were 
characterized and studied by administration of 20 mg/kg doxorubicin HCl i.p. 
 
Infarct Size Determination.  Area at risk and area of infarction were determined by 
perfusing Evans blue dye into the carotid artery prior to sacrificing the animal.  
Hearts were then removed and sectioned perpendicular to the long axis into 1 mm 
slices using a McIlwain tissue chopper (Sterling, Wood Dale, IL) and stained with 1% 
2,3,5-triphenyltetrazolium chloride (TTC) for 5 min at 37˚C.  Each slice was analyzed 
for left ventricular area, area at risk and infarct size. 
 
Measurement of proton relaxation times.  Proton relaxation measurements were 
determined on a custom-built system using a single-sided NMR relaxometer (0.43 T 
and 25˚C; Profile NMR MOUSE, ACT Center for Technology, Aachen, Germany).  The 
sensor’s field gradient enables measurements to be made on a single device 
positioned above the sensor.  Transverse relaxation times for the single-sided MR 
were measured using a Carr Purcell Meiboom Gill (CPMG) sequence with the 
following parameters: echo time (TE) = 0.035 ms, 5714 echoes, 16 scans, and 
recovery time (TR) = 3 s.  The echo peak intensities were fit to the equation  using a 
custom script running on MATLAB (The Mathworks).  
 
Measurement of device dynamics and dosage response. Devices were prepared as 
described above and were individually mounted inside a well on a custom-built 
holder.  Each well was then filled with 400 μL of analyte, and the analyte was 
changed every 4 to 8 hours.  The holder was mounted on an automated motion stage 
and measurements were acquired automatically.  The total exposure is given by the 
integrating the analyte concentration as a function of time and reported in units of 
μg•hr/mL.  Four devices were incubated in a constant concentration (0 ng/mL to 50 
ng/mL) and measured at 20 minute intervals to ascertain the diffusion limited 
response and the onset of saturation.  Six devices were exposed for 4-12 hours to 
myoglobin concentrations of between 30 ng/mL and 100 ng/mL as shown in Figure 
2f (inset).  The analyte was then replaced with PBS, and the devices were incubated 
overnight.  The sensor T2 value stabilizes after approximately 12 hours so 
relaxation times are reported after the overnight incubation.  The return to a zero 
concentration of myoglobin also mimics a transient in vivo event.   
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Magnetic resonance imaging.  MRI measurements were made using a 9.4T animal 
imager (Bruker Biospin).  Imaging protocols included a Tri-plane for localizing the 
implanted devices.  Multi-slice multiecho (MSME) T2-weighted imaging was 
performed using the following parameters: flip angle = 90˚; Matrix size (64 x 64); TR 
= 2330 ms; TE = 16 equally spaced echoes at 4.07 ms intervals ranging from 4.07 ms 
to 85.12 ms; field of view (FOV) = 2 cm x 2 cm, slice thickness = 1 mm.  Region of 
interest analysis was performed and T2 fit was performed using a mono-
exponential fitting algorithm for the multi-TE data.  ROI incorporating the center 
slice of the devices were analyzed.   
 
Statistics.  Statistical comparisons were made by means of the Wilcoxon rank-sum 
two-sided test.  This non-parametric method was considered appropriate here as no 
assumptions are made on the distribution of the data.  P-values of less than 0.05 
were taken to be significant.    
 
 
 
  
 
 
 
 
 
Chapter 5 
  Conclusions and Future Work 
The work conducted in this thesis identifies eNOS phosphorylation and nitric 
oxide bioavailability as important factors in the regulation of ischemic 
postconditioning. The use of genetic mouse models enabled characterization of the 
role of eNOS phosphorylation on myocardial ischemia reperfusion injury in vivo. 
Studies were performed to elucidate the effects of postconditioning on lethal 
reperfusion injury and myocardial  blood flow. These studies reveal that 
postconditioning and eNOS phosphorylation are important protective regulators of 
lethal reperfusion injury (Chapter 2), myocardial blood flow and the no-reflow 
phenomenon  (Chapter 3). The challenge of identifying the left ventricle from Page | 105 
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myocardial contrast echocardiographic images was addressed, and a solution 
applying active contours for image segmentation was presented.  
We encountered limitations in the methods used to evaluate infarct size in 
animal models over the course of this thesis. The need to sacrifice animals to obtain 
ex vivo infarct size data challenges our ability to monitor the temporal development 
of reperfusion injury. In Chapter 4 we present a proof of concept study using 
implantable magnetic relaxation switch sensors to measure cardiac biomarkers and 
estimate infarct size. This technology has potential applications in  small animal 
research where cumulative measurements of biomarkers are difficult to obtain.  
This chapter discusses the general conclusions that may be drawn from this 
thesis   and outlines possible directions for future work.   
 
5.1.  Conclusions 
Postconditioning represents an attractive therapeutic option for the 
treatment of patients with acute myocardial infarction. Preliminary clinical trials 
examining postconditioning as therapies to treat myocardial infarction have shown 
promising results in its the ability to limit myocardial infarction size [87]. However, 
additional basic research is required  to further our understanding of 
cardioprotection and the mechanisms through which postconditioning  exerts its 
protective effects.  Page | 106 
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In this thesis we have identified eNOS phosphorylation at the serine1176 
residue as an important regulator of lethal reperfusion injury and myocardial blood 
flow. Nitric oxide bioavailability is an important determinant of cardioprotective 
success and phosphomimetic modulation of eNOS augments the production of NO. 
Experiments in S1176D knock-in mice show that these benefits translate to 
reductions  in infarct size of over 50%. Moreover, myocardial contrast 
echocardiography studies enable  us to evaluate the pathogenesis of myocardial 
blood flow in a time sensitive manner. We report that blood flow deficits associated 
with reperfusion injury can worsen over time and that postconditioned therapies 
provide beneficial vascular effects. These experiments establish the in vivo 
relevance of posttranslational modification of eNOS in cardioprotection. 
  Our work in image segmentation of MCE videos also demonstrates the 
feasibility of automated tracking in contrast-enhanced  ultrasound videos  of the 
heart. The rapid heart rate of murine models precludes the use of EKG signals and 
we use an active contours approach to identify the myocardium. This approach 
enabled the development of a relatively intuitive and high performance algorithm 
for the analysis of replenishment curves from MCE videos. 
  While there are several gold standard methods to evaluate infarct size and 
myocardial blood flow  in animal models  of myocardial reperfusion injury, the 
established  techniques provide information  at single time points, and  do not 
adequately capture the temporal dynamics of the underlying variable. The Chapter 4 Page | 107 
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we present cumulative biomarker measurements as an attractive option to measure 
the pathogenesis of infarction. Because they MRSw biosensors integrate biomarker 
levels over time, their use in measuring cardiac biomarkers can provide important 
information on the development of reperfusion injury, long after the initial therapy 
has occurred. This opens up the possibility of conducting longitudinal studies in 
small animal models and offers an attractive modality to evaluate the effectiveness 
of cardioprotective therapies. 
 
5.2.  Future Directions 
Postconditioning represents an attractive option for the treatment of acute 
myocardial infarction because its action can be applied at the onset of reperfusion in 
conjunction with other clinical services such as angioplasty.  We  have begun to 
elucidate the mechanisms of action through which the mechanical control of blood 
flow at reperfusion confers cardioprotection in the heart. The signaling pathway 
responsible for the transduction of postconditioning into cardioprotective signaling 
and the reduction in infarct size is likely to involve the posttranslational 
modification of eNOS through phosphorylation.  
The results of this work suggest that phosphorylation of eNOS is sufficient to 
provide protection  against reperfusion injury. Which downstream effectors are 
activated through eNOS phosphorylation will require further investigation. 
Moreover, there are currently no known pharmacological drugs capable of directing Page | 108 
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the phosphorylation eNOS. The design of an assay to evaluate eNOS activity would 
be useful within the framework of large pharmacological drug screen. Identification 
of a compound capable of activating eNOS may provide an invaluable tool against 
acute myocardial infarction. 
eNOS phosphorylation and postconditioning may also prove beneficial for 
the treatment of other pathological processes. The ability to augment NO 
bioavailabilty through the S1176D mutation raises the interesting possibility of 
therapeutic eNOS modulation. The beneficial effects of the S1176D mutation has 
already been reported in models of cerebral ischemia [64] and angiogenesis [63].  
Finally, further investigation into the application of cumulative biomarker 
measurements and  their correlation with disease severity is necessary. The 
application of MRSw sensors will need to be compared against the gold standard 
method for evaluating infarct size for these devices to become useful and reliable 
tools. The use of a biosensor capable of detecting cardiac biomarkers at a very early 
time frame with high sensitivity would be extremely valuable in future basic 
research. 
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